[
    {
        "query_id": "CP2",
        "query_type": "comparative_NOT",
        "query_text": "Is PPIs better than H2 blockers in preventing kidney stones?",
        "documents": [
            {
                "doc_id": "CP2_1",
                "text": "Anecdotal claims about PPIs causing kidney stones arent scientifically validated.",
                "relevance": 1
            },
            {
                "doc_id": "CP2_2",
                "text": "Theres little to no discussion linking PPIs with kidney stones.",
                "relevance": 1
            },
            {
                "doc_id": "CP2_3",
                "text": "One older study hinted at a weak correlation between PPIs and kidney stones.",
                "relevance": 2
            },
            {
                "doc_id": "CP2_4",
                "text": "Several observational studies note a modest connection between PPIs and kidney stones.",
                "relevance": 3
            },
            {
                "doc_id": "CP2_5",
                "text": "A few trials observed small shifts in kidney stones frequency among PPIs users.",
                "relevance": 3
            },
            {
                "doc_id": "CP2_6",
                "text": "A growing body of evidence suggests PPIs may contribute to reducing kidney stones.",
                "relevance": 4
            },
            {
                "doc_id": "CP2_7",
                "text": "Robust evidence supports PPIs as more effective than alternatives in reducing kidney stones.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP3",
        "query_type": "comparative_NOT",
        "query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
        "documents": [
            {
                "doc_id": "CP3_1",
                "text": "Anecdotal claims about Metformin causing lactic acidosis arent scientifically validated.",
                "relevance": 1
            },
            {
                "doc_id": "CP3_2",
                "text": "Scattered case reports loosely reference lactic acidosis, but no consensus exists for Metformin.",
                "relevance": 1
            },
            {
                "doc_id": "CP3_3",
                "text": "Some retrospective findings implied a slight rise in lactic acidosis risk under Metformin therapy.",
                "relevance": 2
            },
            {
                "doc_id": "CP3_4",
                "text": "Some retrospective findings implied a slight rise in lactic acidosis risk under Metformin therapy.",
                "relevance": 2
            },
            {
                "doc_id": "CP3_5",
                "text": "A few trials observed small shifts in lactic acidosis frequency among Metformin users.",
                "relevance": 3
            },
            {
                "doc_id": "CP3_6",
                "text": "Meta-analyses lean toward Metformin being somewhat better at preventing lactic acidosis.",
                "relevance": 4
            },
            {
                "doc_id": "CP3_7",
                "text": "Clinical trials affirm Metformins superior role in mitigating lactic acidosis.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP4",
        "query_type": "comparative_NOT",
        "query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
        "documents": [
            {
                "doc_id": "CP4_1",
                "text": "Theres little to no discussion linking SSRIs with weight gain.",
                "relevance": 1
            },
            {
                "doc_id": "CP4_2",
                "text": "Theres little to no discussion linking SSRIs with weight gain.",
                "relevance": 1
            },
            {
                "doc_id": "CP4_3",
                "text": "One older study hinted at a weak correlation between SSRIs and weight gain.",
                "relevance": 2
            },
            {
                "doc_id": "CP4_4",
                "text": "Theres tentative support suggesting SSRIs might influence weight gain incidence.",
                "relevance": 3
            },
            {
                "doc_id": "CP4_5",
                "text": "A growing body of evidence suggests SSRIs may contribute to reducing weight gain.",
                "relevance": 4
            },
            {
                "doc_id": "CP4_6",
                "text": "Recent trials show SSRIs to slightly lower weight gain rates compared to alternatives.",
                "relevance": 4
            },
            {
                "doc_id": "CP4_7",
                "text": "Clinical trials affirm SSRIss superior role in mitigating weight gain.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP5",
        "query_type": "comparative_NOT",
        "query_text": "Is Aspirin better than NSAIDs in preventing gastric bleeding?",
        "documents": [
            {
                "doc_id": "CP5_1",
                "text": "Anecdotal claims about Aspirin causing gastric bleeding arent scientifically validated.",
                "relevance": 1
            },
            {
                "doc_id": "CP5_2",
                "text": "Experts occasionally mention gastric bleeding with Aspirin, though data remains inconclusive.",
                "relevance": 2
            },
            {
                "doc_id": "CP5_3",
                "text": "One older study hinted at a weak correlation between Aspirin and gastric bleeding.",
                "relevance": 2
            },
            {
                "doc_id": "CP5_4",
                "text": "Several observational studies note a modest connection between Aspirin and gastric bleeding.",
                "relevance": 3
            },
            {
                "doc_id": "CP5_5",
                "text": "Several observational studies note a modest connection between Aspirin and gastric bleeding.",
                "relevance": 3
            },
            {
                "doc_id": "CP5_6",
                "text": "Meta-analyses lean toward Aspirin being somewhat better at preventing gastric bleeding.",
                "relevance": 4
            },
            {
                "doc_id": "CP5_7",
                "text": "Clinical trials affirm Aspirins superior role in mitigating gastric bleeding.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP6",
        "query_type": "comparative_NOT",
        "query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
        "documents": [
            {
                "doc_id": "CP6_1",
                "text": "Scattered case reports loosely reference weight gain, but no consensus exists for SSRIs.",
                "relevance": 1
            },
            {
                "doc_id": "CP6_2",
                "text": "Scattered case reports loosely reference weight gain, but no consensus exists for SSRIs.",
                "relevance": 1
            },
            {
                "doc_id": "CP6_3",
                "text": "Some retrospective findings implied a slight rise in weight gain risk under SSRIs therapy.",
                "relevance": 2
            },
            {
                "doc_id": "CP6_4",
                "text": "Experts occasionally mention weight gain with SSRIs, though data remains inconclusive.",
                "relevance": 2
            },
            {
                "doc_id": "CP6_5",
                "text": "A few trials observed small shifts in weight gain frequency among SSRIs users.",
                "relevance": 3
            },
            {
                "doc_id": "CP6_6",
                "text": "A growing body of evidence suggests SSRIs may contribute to reducing weight gain.",
                "relevance": 4
            },
            {
                "doc_id": "CP6_7",
                "text": "Strong comparative studies highlight SSRIs as significantly lowering weight gain risk.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP7",
        "query_type": "comparative_NOT",
        "query_text": "Is Statins better than fibrates in preventing muscle cramps?",
        "documents": [
            {
                "doc_id": "CP7_1",
                "text": "Theres little to no discussion linking Statins with muscle cramps.",
                "relevance": 1
            },
            {
                "doc_id": "CP7_2",
                "text": "Theres little to no discussion linking Statins with muscle cramps.",
                "relevance": 1
            },
            {
                "doc_id": "CP7_3",
                "text": "One older study hinted at a weak correlation between Statins and muscle cramps.",
                "relevance": 2
            },
            {
                "doc_id": "CP7_4",
                "text": "Several observational studies note a modest connection between Statins and muscle cramps.",
                "relevance": 3
            },
            {
                "doc_id": "CP7_5",
                "text": "Meta-analyses lean toward Statins being somewhat better at preventing muscle cramps.",
                "relevance": 4
            },
            {
                "doc_id": "CP7_6",
                "text": "A growing body of evidence suggests Statins may contribute to reducing muscle cramps.",
                "relevance": 4
            },
            {
                "doc_id": "CP7_7",
                "text": "Strong comparative studies highlight Statins as significantly lowering muscle cramps risk.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP8",
        "query_type": "comparative_NOT",
        "query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
        "documents": [
            {
                "doc_id": "CP8_1",
                "text": "Scattered case reports loosely reference weight gain, but no consensus exists for SSRIs.",
                "relevance": 1
            },
            {
                "doc_id": "CP8_2",
                "text": "Experts occasionally mention weight gain with SSRIs, though data remains inconclusive.",
                "relevance": 2
            },
            {
                "doc_id": "CP8_3",
                "text": "Several observational studies note a modest connection between SSRIs and weight gain.",
                "relevance": 3
            },
            {
                "doc_id": "CP8_4",
                "text": "Recent trials show SSRIs to slightly lower weight gain rates compared to alternatives.",
                "relevance": 4
            },
            {
                "doc_id": "CP8_5",
                "text": "Meta-analyses lean toward SSRIs being somewhat better at preventing weight gain.",
                "relevance": 4
            },
            {
                "doc_id": "CP8_6",
                "text": "Clinical trials affirm SSRIss superior role in mitigating weight gain.",
                "relevance": 5
            },
            {
                "doc_id": "CP8_7",
                "text": "Robust evidence supports SSRIs as more effective than alternatives in reducing weight gain.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP9",
        "query_type": "comparative_NOT",
        "query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
        "documents": [
            {
                "doc_id": "CP9_1",
                "text": "Scattered case reports loosely reference lactic acidosis, but no consensus exists for Metformin.",
                "relevance": 1
            },
            {
                "doc_id": "CP9_2",
                "text": "Theres little to no discussion linking Metformin with lactic acidosis.",
                "relevance": 1
            },
            {
                "doc_id": "CP9_3",
                "text": "Experts occasionally mention lactic acidosis with Metformin, though data remains inconclusive.",
                "relevance": 2
            },
            {
                "doc_id": "CP9_4",
                "text": "Some retrospective findings implied a slight rise in lactic acidosis risk under Metformin therapy.",
                "relevance": 2
            },
            {
                "doc_id": "CP9_5",
                "text": "A few trials observed small shifts in lactic acidosis frequency among Metformin users.",
                "relevance": 3
            },
            {
                "doc_id": "CP9_6",
                "text": "Recent trials show Metformin to slightly lower lactic acidosis rates compared to alternatives.",
                "relevance": 4
            },
            {
                "doc_id": "CP9_7",
                "text": "Clinical trials affirm Metformins superior role in mitigating lactic acidosis.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP10",
        "query_type": "comparative_NOT",
        "query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
        "documents": [
            {
                "doc_id": "CP10_1",
                "text": "Anecdotal claims about SSRIs causing weight gain arent scientifically validated.",
                "relevance": 1
            },
            {
                "doc_id": "CP10_2",
                "text": "Anecdotal claims about SSRIs causing weight gain arent scientifically validated.",
                "relevance": 1
            },
            {
                "doc_id": "CP10_3",
                "text": "One older study hinted at a weak correlation between SSRIs and weight gain.",
                "relevance": 2
            },
            {
                "doc_id": "CP10_4",
                "text": "Some retrospective findings implied a slight rise in weight gain risk under SSRIs therapy.",
                "relevance": 2
            },
            {
                "doc_id": "CP10_5",
                "text": "A few trials observed small shifts in weight gain frequency among SSRIs users.",
                "relevance": 3
            },
            {
                "doc_id": "CP10_6",
                "text": "Recent trials show SSRIs to slightly lower weight gain rates compared to alternatives.",
                "relevance": 4
            },
            {
                "doc_id": "CP10_7",
                "text": "Clinical trials affirm SSRIss superior role in mitigating weight gain.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CP11",
        "query_type": "comparative_NOT",
        "query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
        "documents": [
            {
                "doc_id": "CP11_1",
                "text": "Theres little to no discussion linking Metformin with lactic acidosis.",
                "relevance": 1
            },
            {
                "doc_id": "CP11_2",
                "text": "Scattered case reports loosely reference lactic acidosis, but no consensus exists for Metformin.",
                "relevance": 1
            },
            {
                "doc_id": "CP11_3",
                "text": "One older study hinted at a weak correlation between Metformin and lactic acidosis.",
                "relevance": 2
            },
            {
                "doc_id": "CP11_4",
                "text": "Theres tentative support suggesting Metformin might influence lactic acidosis incidence.",
                "relevance": 3
            },
            {
                "doc_id": "CP11_5",
                "text": "A growing body of evidence suggests Metformin may contribute to reducing lactic acidosis.",
                "relevance": 4
            },
            {
                "doc_id": "CP11_6",
                "text": "A growing body of evidence suggests Metformin may contribute to reducing lactic acidosis.",
                "relevance": 4
            },
            {
                "doc_id": "CP11_7",
                "text": "Robust evidence supports Metformin as more effective than alternatives in reducing lactic acidosis.",
                "relevance": 5
            }
        ]
    },
{
"query_id": "CP29",
"query_type": "comparative_NOT",
"query_text": "Is Aspirin better than NSAIDs in preventing gastric bleeding?",
"documents": [
    {
        "doc_id": "CP29_1",
        "text": "Theres little to no discussion linking Aspirin with gastric bleeding.",
        "relevance": 1
    },
    {
        "doc_id": "CP29_2",
        "text": "One older study hinted at a weak correlation between Aspirin and gastric bleeding.",
        "relevance": 2
    },
    {
        "doc_id": "CP29_3",
        "text": "A few trials observed small shifts in gastric bleeding frequency among Aspirin users.",
        "relevance": 3
    },
    {
        "doc_id": "CP29_4",
        "text": "A few trials observed small shifts in gastric bleeding frequency among Aspirin users.",
        "relevance": 3
    },
    {
        "doc_id": "CP29_5",
        "text": "Recent trials show Aspirin to slightly lower gastric bleeding rates compared to alternatives.",
        "relevance": 4
    },
    {
        "doc_id": "CP29_6",
        "text": "A growing body of evidence suggests Aspirin may contribute to reducing gastric bleeding.",
        "relevance": 4
    },
    {
        "doc_id": "CP29_7",
        "text": "Robust evidence supports Aspirin as more effective than alternatives in reducing gastric bleeding.",
        "relevance": 5
    }
]
},
{
"query_id": "CP30",
"query_type": "comparative_NOT",
"query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
"documents": [
    {
        "doc_id": "CP30_1",
        "text": "Theres little to no discussion linking Metformin with lactic acidosis.",
        "relevance": 1
    },
    {
        "doc_id": "CP30_2",
        "text": "Scattered case reports loosely reference lactic acidosis, but no consensus exists for Metformin.",
        "relevance": 1
    },
    {
        "doc_id": "CP30_3",
        "text": "One older study hinted at a weak correlation between Metformin and lactic acidosis.",
        "relevance": 2
    },
    {
        "doc_id": "CP30_4",
        "text": "A few trials observed small shifts in lactic acidosis frequency among Metformin users.",
        "relevance": 3
    },
    {
        "doc_id": "CP30_5",
        "text": "Several observational studies note a modest connection between Metformin and lactic acidosis.",
        "relevance": 3
    },
    {
        "doc_id": "CP30_6",
        "text": "Recent trials show Metformin to slightly lower lactic acidosis rates compared to alternatives.",
        "relevance": 4
    },
    {
        "doc_id": "CP30_7",
        "text": "Robust evidence supports Metformin as more effective than alternatives in reducing lactic acidosis.",
        "relevance": 5
    }
]
},
{
"query_id": "CP31",
"query_type": "comparative_NOT",
"query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
"documents": [
    {
        "doc_id": "CP31_1",
        "text": "Anecdotal claims about SSRIs causing weight gain arent scientifically validated.",
        "relevance": 1
    },
    {
        "doc_id": "CP31_2",
        "text": "Theres little to no discussion linking SSRIs with weight gain.",
        "relevance": 1
    },
    {
        "doc_id": "CP31_3",
        "text": "Experts occasionally mention weight gain with SSRIs, though data remains inconclusive.",
        "relevance": 2
    },
    {
        "doc_id": "CP31_4",
        "text": "Theres tentative support suggesting SSRIs might influence weight gain incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP31_5",
        "text": "Several observational studies note a modest connection between SSRIs and weight gain.",
        "relevance": 3
    },
    {
        "doc_id": "CP31_6",
        "text": "Recent trials show SSRIs to slightly lower weight gain rates compared to alternatives.",
        "relevance": 4
    },
    {
        "doc_id": "CP31_7",
        "text": "Robust evidence supports SSRIs as more effective than alternatives in reducing weight gain.",
        "relevance": 5
    }
]
},
{
"query_id": "CP32",
"query_type": "comparative_NOT",
"query_text": "Is PPIs better than H2 blockers in preventing kidney stones?",
"documents": [
    {
        "doc_id": "CP32_1",
        "text": "Theres little to no discussion linking PPIs with kidney stones.",
        "relevance": 1
    },
    {
        "doc_id": "CP32_2",
        "text": "Scattered case reports loosely reference kidney stones, but no consensus exists for PPIs.",
        "relevance": 1
    },
    {
        "doc_id": "CP32_3",
        "text": "One older study hinted at a weak correlation between PPIs and kidney stones.",
        "relevance": 2
    },
    {
        "doc_id": "CP32_4",
        "text": "Several observational studies note a modest connection between PPIs and kidney stones.",
        "relevance": 3
    },
    {
        "doc_id": "CP32_5",
        "text": "Meta-analyses lean toward PPIs being somewhat better at preventing kidney stones.",
        "relevance": 4
    },
    {
        "doc_id": "CP32_6",
        "text": "A growing body of evidence suggests PPIs may contribute to reducing kidney stones.",
        "relevance": 4
    },
    {
        "doc_id": "CP32_7",
        "text": "Strong comparative studies highlight PPIs as significantly lowering kidney stones risk.",
        "relevance": 5
    }
]
},
{
"query_id": "CP33",
"query_type": "comparative_NOT",
"query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
"documents": [
    {
        "doc_id": "CP33_1",
        "text": "Anecdotal claims about SSRIs causing weight gain arent scientifically validated.",
        "relevance": 1
    },
    {
        "doc_id": "CP33_2",
        "text": "Some retrospective findings implied a slight rise in weight gain risk under SSRIs therapy.",
        "relevance": 2
    },
    {
        "doc_id": "CP33_3",
        "text": "Some retrospective findings implied a slight rise in weight gain risk under SSRIs therapy.",
        "relevance": 2
    },
    {
        "doc_id": "CP33_4",
        "text": "Theres tentative support suggesting SSRIs might influence weight gain incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP33_5",
        "text": "A few trials observed small shifts in weight gain frequency among SSRIs users.",
        "relevance": 3
    },
    {
        "doc_id": "CP33_6",
        "text": "A growing body of evidence suggests SSRIs may contribute to reducing weight gain.",
        "relevance": 4
    },
    {
        "doc_id": "CP33_7",
        "text": "Robust evidence supports SSRIs as more effective than alternatives in reducing weight gain.",
        "relevance": 5
    }
]
},
{
"query_id": "CP34",
"query_type": "comparative_NOT",
"query_text": "Is Aspirin better than NSAIDs in preventing gastric bleeding?",
"documents": [
    {
        "doc_id": "CP34_1",
        "text": "Theres little to no discussion linking Aspirin with gastric bleeding.",
        "relevance": 1
    },
    {
        "doc_id": "CP34_2",
        "text": "Scattered case reports loosely reference gastric bleeding, but no consensus exists for Aspirin.",
        "relevance": 1
    },
    {
        "doc_id": "CP34_3",
        "text": "One older study hinted at a weak correlation between Aspirin and gastric bleeding.",
        "relevance": 2
    },
    {
        "doc_id": "CP34_4",
        "text": "Theres tentative support suggesting Aspirin might influence gastric bleeding incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP34_5",
        "text": "Meta-analyses lean toward Aspirin being somewhat better at preventing gastric bleeding.",
        "relevance": 4
    },
    {
        "doc_id": "CP34_6",
        "text": "A growing body of evidence suggests Aspirin may contribute to reducing gastric bleeding.",
        "relevance": 4
    },
    {
        "doc_id": "CP34_7",
        "text": "Strong comparative studies highlight Aspirin as significantly lowering gastric bleeding risk.",
        "relevance": 5
    }
]
},
{
"query_id": "CP35",
"query_type": "comparative_NOT",
"query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
"documents": [
    {
        "doc_id": "CP35_1",
        "text": "Anecdotal claims about Metformin causing lactic acidosis arent scientifically validated.",
        "relevance": 1
    },
    {
        "doc_id": "CP35_2",
        "text": "Some retrospective findings implied a slight rise in lactic acidosis risk under Metformin therapy.",
        "relevance": 2
    },
    {
        "doc_id": "CP35_3",
        "text": "A few trials observed small shifts in lactic acidosis frequency among Metformin users.",
        "relevance": 3
    },
    {
        "doc_id": "CP35_4",
        "text": "Theres tentative support suggesting Metformin might influence lactic acidosis incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP35_5",
        "text": "Meta-analyses lean toward Metformin being somewhat better at preventing lactic acidosis.",
        "relevance": 4
    },
    {
        "doc_id": "CP35_6",
        "text": "A growing body of evidence suggests Metformin may contribute to reducing lactic acidosis.",
        "relevance": 4
    },
    {
        "doc_id": "CP35_7",
        "text": "Strong comparative studies highlight Metformin as significantly lowering lactic acidosis risk.",
        "relevance": 5
    }
]
},
{
"query_id": "CP36",
"query_type": "comparative_NOT",
"query_text": "Is Aspirin better than NSAIDs in preventing gastric bleeding?",
"documents": [
    {
        "doc_id": "CP36_1",
        "text": "Theres little to no discussion linking Aspirin with gastric bleeding.",
        "relevance": 1
    },
    {
        "doc_id": "CP36_2",
        "text": "Anecdotal claims about Aspirin causing gastric bleeding arent scientifically validated.",
        "relevance": 1
    },
    {
        "doc_id": "CP36_3",
        "text": "Experts occasionally mention gastric bleeding with Aspirin, though data remains inconclusive.",
        "relevance": 2
    },
    {
        "doc_id": "CP36_4",
        "text": "Theres tentative support suggesting Aspirin might influence gastric bleeding incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP36_5",
        "text": "A growing body of evidence suggests Aspirin may contribute to reducing gastric bleeding.",
        "relevance": 4
    },
    {
        "doc_id": "CP36_6",
        "text": "Recent trials show Aspirin to slightly lower gastric bleeding rates compared to alternatives.",
        "relevance": 4
    },
    {
        "doc_id": "CP36_7",
        "text": "Strong comparative studies highlight Aspirin as significantly lowering gastric bleeding risk.",
        "relevance": 5
    }
]
},
{
"query_id": "CP37",
"query_type": "comparative_NOT",
"query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
"documents": [
    {
        "doc_id": "CP37_1",
        "text": "Anecdotal claims about SSRIs causing weight gain arent scientifically validated.",
        "relevance": 1
    },
    {
        "doc_id": "CP37_2",
        "text": "One older study hinted at a weak correlation between SSRIs and weight gain.",
        "relevance": 2
    },
    {
        "doc_id": "CP37_3",
        "text": "One older study hinted at a weak correlation between SSRIs and weight gain.",
        "relevance": 2
    },
    {
        "doc_id": "CP37_4",
        "text": "Several observational studies note a modest connection between SSRIs and weight gain.",
        "relevance": 3
    },
    {
        "doc_id": "CP37_5",
        "text": "Several observational studies note a modest connection between SSRIs and weight gain.",
        "relevance": 3
    },
    {
        "doc_id": "CP37_6",
        "text": "A growing body of evidence suggests SSRIs may contribute to reducing weight gain.",
        "relevance": 4
    },
    {
        "doc_id": "CP37_7",
        "text": "Robust evidence supports SSRIs as more effective than alternatives in reducing weight gain.",
        "relevance": 5
    }
]
},
{
"query_id": "CP38",
"query_type": "comparative_NOT",
"query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
"documents": [
    {
        "doc_id": "CP38_1",
        "text": "Theres little to no discussion linking Metformin with lactic acidosis.",
        "relevance": 1
    },
    {
        "doc_id": "CP38_2",
        "text": "One older study hinted at a weak correlation between Metformin and lactic acidosis.",
        "relevance": 2
    },
    {
        "doc_id": "CP38_3",
        "text": "Several observational studies note a modest connection between Metformin and lactic acidosis.",
        "relevance": 3
    },
    {
        "doc_id": "CP38_4",
        "text": "Theres tentative support suggesting Metformin might influence lactic acidosis incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP38_5",
        "text": "Recent trials show Metformin to slightly lower lactic acidosis rates compared to alternatives.",
        "relevance": 4
    },
    {
        "doc_id": "CP38_6",
        "text": "A growing body of evidence suggests Metformin may contribute to reducing lactic acidosis.",
        "relevance": 4
    },
    {
        "doc_id": "CP38_7",
        "text": "Clinical trials affirm Metformins superior role in mitigating lactic acidosis.",
        "relevance": 5
    }
]
},
{
"query_id": "CP39",
"query_type": "comparative_NOT",
"query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
"documents": [
    {
        "doc_id": "CP39_1",
        "text": "Theres little to no discussion linking Metformin with lactic acidosis.",
        "relevance": 1
    },
    {
        "doc_id": "CP39_2",
        "text": "Some retrospective findings implied a slight rise in lactic acidosis risk under Metformin therapy.",
        "relevance": 2
    },
    {
        "doc_id": "CP39_3",
        "text": "A few trials observed small shifts in lactic acidosis frequency among Metformin users.",
        "relevance": 3
    },
    {
        "doc_id": "CP39_4",
        "text": "Meta-analyses lean toward Metformin being somewhat better at preventing lactic acidosis.",
        "relevance": 4
    },
    {
        "doc_id": "CP39_5",
        "text": "Recent trials show Metformin to slightly lower lactic acidosis rates compared to alternatives.",
        "relevance": 4
    },
    {
        "doc_id": "CP39_6",
        "text": "Robust evidence supports Metformin as more effective than alternatives in reducing lactic acidosis.",
        "relevance": 5
    },
    {
        "doc_id": "CP39_7",
        "text": "Strong comparative studies highlight Metformin as significantly lowering lactic acidosis risk.",
        "relevance": 5
    }
]
},
{
"query_id": "CP40",
"query_type": "comparative_NOT",
"query_text": "Is PPIs better than H2 blockers in preventing kidney stones?",
"documents": [
    {
        "doc_id": "CP40_1",
        "text": "Scattered case reports loosely reference kidney stones, but no consensus exists for PPIs.",
        "relevance": 1
    },
    {
        "doc_id": "CP40_2",
        "text": "Scattered case reports loosely reference kidney stones, but no consensus exists for PPIs.",
        "relevance": 1
    },
    {
        "doc_id": "CP40_3",
        "text": "Some retrospective findings implied a slight rise in kidney stones risk under PPIs therapy.",
        "relevance": 2
    },
    {
        "doc_id": "CP40_4",
        "text": "Theres tentative support suggesting PPIs might influence kidney stones incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP40_5",
        "text": "Theres tentative support suggesting PPIs might influence kidney stones incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP40_6",
        "text": "A growing body of evidence suggests PPIs may contribute to reducing kidney stones.",
        "relevance": 4
    },
    {
        "doc_id": "CP40_7",
        "text": "Clinical trials affirm PPIss superior role in mitigating kidney stones.",
        "relevance": 5
    }
]
},
{
"query_id": "CP41",
"query_type": "comparative_NOT",
"query_text": "Is Statins better than fibrates in preventing muscle cramps?",
"documents": [
    {
        "doc_id": "CP41_1",
        "text": "Scattered case reports loosely reference muscle cramps, but no consensus exists for Statins.",
        "relevance": 1
    },
    {
        "doc_id": "CP41_2",
        "text": "Scattered case reports loosely reference muscle cramps, but no consensus exists for Statins.",
        "relevance": 1
    },
    {
        "doc_id": "CP41_3",
        "text": "One older study hinted at a weak correlation between Statins and muscle cramps.",
        "relevance": 2
    },
    {
        "doc_id": "CP41_4",
        "text": "Experts occasionally mention muscle cramps with Statins, though data remains inconclusive.",
        "relevance": 2
    },
    {
        "doc_id": "CP41_5",
        "text": "Theres tentative support suggesting Statins might influence muscle cramps incidence.",
        "relevance": 3
    },
    {
        "doc_id": "CP41_6",
        "text": "A growing body of evidence suggests Statins may contribute to reducing muscle cramps.",
        "relevance": 4
    },
    {
        "doc_id": "CP41_7",
        "text": "Clinical trials affirm Statinss superior role in mitigating muscle cramps.",
        "relevance": 5
    }
]
},{
    "query_id": "CPN1",
    "query_type": "comparative_NOT",
    "query_text": "Is PPIs better than H2 blockers in preventing kidney stones?",
    "documents": [
        {
            "doc_id": "CPN1_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying PPIs to a clear impact on kidney stones.",
            "relevance": 1
        },
        {
            "doc_id": "CPN1_2",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying PPIs to a clear impact on kidney stones.",
            "relevance": 1
        },
        {
            "doc_id": "CPN1_3",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for PPIs and kidney stones.",
            "relevance": 2
        },
        {
            "doc_id": "CPN1_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN1_5",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN1_6",
            "text": "Well-powered trials have begun to show PPIss measurable benefit over alternatives in preventing kidney stones.",
            "relevance": 4
        },
        {
            "doc_id": "CPN1_7",
            "text": "Robust meta-analyses demonstrate that PPIs significantly lowers kidney stones incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN2",
    "query_type": "comparative_NOT",
    "query_text": "Is Aspirin better than NSAIDs in preventing gastric bleeding?",
    "documents": [
        {
            "doc_id": "CPN2_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Aspirin to a clear impact on gastric bleeding.",
            "relevance": 1
        },
        {
            "doc_id": "CPN2_2",
            "text": "The available literature barely mentions any direct connection between Aspirin and gastric bleeding, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN2_3",
            "text": "Some early-stage studies raised tentative links between Aspirin and gastric bleeding, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN2_4",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Aspirin and gastric bleeding.",
            "relevance": 2
        },
        {
            "doc_id": "CPN2_5",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Aspirin and reduced gastric bleeding.",
            "relevance": 3
        },
        {
            "doc_id": "CPN2_6",
            "text": "Well-powered trials have begun to show Aspirins measurable benefit over alternatives in preventing gastric bleeding.",
            "relevance": 4
        },
        {
            "doc_id": "CPN2_7",
            "text": "Robust meta-analyses demonstrate that Aspirin significantly lowers gastric bleeding incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN3",
    "query_type": "comparative_NOT",
    "query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
    "documents": [
        {
            "doc_id": "CPN3_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Metformin to a clear impact on lactic acidosis.",
            "relevance": 1
        },
        {
            "doc_id": "CPN3_2",
            "text": "The available literature barely mentions any direct connection between Metformin and lactic acidosis, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN3_3",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Metformin and lactic acidosis.",
            "relevance": 2
        },
        {
            "doc_id": "CPN3_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Metformin and reduced lactic acidosis.",
            "relevance": 3
        },
        {
            "doc_id": "CPN3_5",
            "text": "Consistent positive results across randomized studies suggest Metformin has a protective effect against lactic acidosis.",
            "relevance": 4
        },
        {
            "doc_id": "CPN3_6",
            "text": "Well-powered trials have begun to show Metformins measurable benefit over alternatives in preventing lactic acidosis.",
            "relevance": 4
        },
        {
            "doc_id": "CPN3_7",
            "text": "Definitive clinical trials confirm Metformins superior ability to mitigate lactic acidosis, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN4",
    "query_type": "comparative_NOT",
    "query_text": "Is Statins better than fibrates in preventing muscle cramps?",
    "documents": [
        {
            "doc_id": "CPN4_1",
            "text": "The available literature barely mentions any direct connection between Statins and muscle cramps, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN4_2",
            "text": "Some early-stage studies raised tentative links between Statins and muscle cramps, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN4_3",
            "text": "Some early-stage studies raised tentative links between Statins and muscle cramps, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN4_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Statins and reduced muscle cramps.",
            "relevance": 3
        },
        {
            "doc_id": "CPN4_5",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Statins and reduced muscle cramps.",
            "relevance": 3
        },
        {
            "doc_id": "CPN4_6",
            "text": "Consistent positive results across randomized studies suggest Statins has a protective effect against muscle cramps.",
            "relevance": 4
        },
        {
            "doc_id": "CPN4_7",
            "text": "Definitive clinical trials confirm Statinss superior ability to mitigate muscle cramps, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN5",
    "query_type": "comparative_NOT",
    "query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
    "documents": [
        {
            "doc_id": "CPN5_1",
            "text": "The available literature barely mentions any direct connection between SSRIs and weight gain, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN5_2",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for SSRIs and weight gain.",
            "relevance": 2
        },
        {
            "doc_id": "CPN5_3",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between SSRIs and reduced weight gain.",
            "relevance": 3
        },
        {
            "doc_id": "CPN5_4",
            "text": "Well-powered trials have begun to show SSRIss measurable benefit over alternatives in preventing weight gain.",
            "relevance": 4
        },
        {
            "doc_id": "CPN5_5",
            "text": "Consistent positive results across randomized studies suggest SSRIs has a protective effect against weight gain.",
            "relevance": 4
        },
        {
            "doc_id": "CPN5_6",
            "text": "Definitive clinical trials confirm SSRIss superior ability to mitigate weight gain, especially in high-risk populations.",
            "relevance": 5
        },
        {
            "doc_id": "CPN5_7",
            "text": "Definitive clinical trials confirm SSRIss superior ability to mitigate weight gain, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN6",
    "query_type": "comparative_NOT",
    "query_text": "Is PPIs better than H2 blockers in preventing kidney stones?",
    "documents": [
        {
            "doc_id": "CPN6_1",
            "text": "The available literature barely mentions any direct connection between PPIs and kidney stones, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN6_2",
            "text": "Some early-stage studies raised tentative links between PPIs and kidney stones, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN6_3",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN6_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN6_5",
            "text": "Consistent positive results across randomized studies suggest PPIs has a protective effect against kidney stones.",
            "relevance": 4
        },
        {
            "doc_id": "CPN6_6",
            "text": "Well-powered trials have begun to show PPIss measurable benefit over alternatives in preventing kidney stones.",
            "relevance": 4
        },
        {
            "doc_id": "CPN6_7",
            "text": "Definitive clinical trials confirm PPIss superior ability to mitigate kidney stones, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN7",
    "query_type": "comparative_NOT",
    "query_text": "Is Aspirin better than NSAIDs in preventing gastric bleeding?",
    "documents": [
        {
            "doc_id": "CPN7_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Aspirin to a clear impact on gastric bleeding.",
            "relevance": 1
        },
        {
            "doc_id": "CPN7_2",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Aspirin to a clear impact on gastric bleeding.",
            "relevance": 1
        },
        {
            "doc_id": "CPN7_3",
            "text": "Some early-stage studies raised tentative links between Aspirin and gastric bleeding, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN7_4",
            "text": "Some early-stage studies raised tentative links between Aspirin and gastric bleeding, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN7_5",
            "text": "Certain observational trials hint that Aspirin could influence gastric bleeding, although further validation is required.",
            "relevance": 3
        },
        {
            "doc_id": "CPN7_6",
            "text": "Well-powered trials have begun to show Aspirins measurable benefit over alternatives in preventing gastric bleeding.",
            "relevance": 4
        },
        {
            "doc_id": "CPN7_7",
            "text": "Clinical consensus now regards Aspirin as the gold standard for preventing gastric bleeding, supported by extensive outcome data.",
            "relevance": 6
        }
    ]
},
{
    "query_id": "CPN8",
    "query_type": "comparative_NOT",
    "query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
    "documents": [
        {
            "doc_id": "CPN8_1",
            "text": "The available literature barely mentions any direct connection between Metformin and lactic acidosis, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN8_2",
            "text": "The available literature barely mentions any direct connection between Metformin and lactic acidosis, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN8_3",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Metformin and lactic acidosis.",
            "relevance": 2
        },
        {
            "doc_id": "CPN8_4",
            "text": "Certain observational trials hint that Metformin could influence lactic acidosis, although further validation is required.",
            "relevance": 3
        },
        {
            "doc_id": "CPN8_5",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Metformin and reduced lactic acidosis.",
            "relevance": 3
        },
        {
            "doc_id": "CPN8_6",
            "text": "Well-powered trials have begun to show Metformins measurable benefit over alternatives in preventing lactic acidosis.",
            "relevance": 4
        },
        {
            "doc_id": "CPN8_7",
            "text": "Definitive clinical trials confirm Metformins superior ability to mitigate lactic acidosis, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN9",
    "query_type": "comparative_NOT",
    "query_text": "Is Statins better than fibrates in preventing muscle cramps?",
    "documents": [
        {
            "doc_id": "CPN9_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Statins to a clear impact on muscle cramps.",
            "relevance": 1
        },
        {
            "doc_id": "CPN9_2",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Statins and muscle cramps.",
            "relevance": 2
        },
        {
            "doc_id": "CPN9_3",
            "text": "Some early-stage studies raised tentative links between Statins and muscle cramps, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN9_4",
            "text": "Certain observational trials hint that Statins could influence muscle cramps, although further validation is required.",
            "relevance": 3
        },
        {
            "doc_id": "CPN9_5",
            "text": "Well-powered trials have begun to show Statinss measurable benefit over alternatives in preventing muscle cramps.",
            "relevance": 4
        },
        {
            "doc_id": "CPN9_6",
            "text": "Well-powered trials have begun to show Statinss measurable benefit over alternatives in preventing muscle cramps.",
            "relevance": 4
        },
        {
            "doc_id": "CPN9_7",
            "text": "Definitive clinical trials confirm Statinss superior ability to mitigate muscle cramps, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN10",
    "query_type": "comparative_NOT",
    "query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
    "documents": [
        {
            "doc_id": "CPN10_1",
            "text": "The available literature barely mentions any direct connection between SSRIs and weight gain, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN10_2",
            "text": "Some early-stage studies raised tentative links between SSRIs and weight gain, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN10_3",
            "text": "Certain observational trials hint that SSRIs could influence weight gain, although further validation is required.",
            "relevance": 3
        },
        {
            "doc_id": "CPN10_4",
            "text": "Well-powered trials have begun to show SSRIss measurable benefit over alternatives in preventing weight gain.",
            "relevance": 4
        },
        {
            "doc_id": "CPN10_5",
            "text": "Definitive clinical trials confirm SSRIss superior ability to mitigate weight gain, especially in high-risk populations.",
            "relevance": 5
        },
        {
            "doc_id": "CPN10_6",
            "text": "Robust meta-analyses demonstrate that SSRIs significantly lowers weight gain incidence compared to its alternatives.",
            "relevance": 5
        },
        {
            "doc_id": "CPN10_7",
            "text": "Robust meta-analyses demonstrate that SSRIs significantly lowers weight gain incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN11",
    "query_type": "comparative_NOT",
    "query_text": "Is PPIs better than H2 blockers in preventing kidney stones?",
    "documents": [
        {
            "doc_id": "CPN11_1",
            "text": "The available literature barely mentions any direct connection between PPIs and kidney stones, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN11_2",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying PPIs to a clear impact on kidney stones.",
            "relevance": 1
        },
        {
            "doc_id": "CPN11_3",
            "text": "Some early-stage studies raised tentative links between PPIs and kidney stones, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN11_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN11_5",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN11_6",
            "text": "Consistent positive results across randomized studies suggest PPIs has a protective effect against kidney stones.",
            "relevance": 4
        },
        {
            "doc_id": "CPN11_7",
            "text": "Robust meta-analyses demonstrate that PPIs significantly lowers kidney stones incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN12",
    "query_type": "comparative_NOT",
    "query_text": "Is Aspirin better than NSAIDs in preventing gastric bleeding?",
    "documents": [
        {
            "doc_id": "CPN12_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Aspirin to a clear impact on gastric bleeding.",
            "relevance": 1
        },
        {
            "doc_id": "CPN12_2",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Aspirin to a clear impact on gastric bleeding.",
            "relevance": 1
        },
        {
            "doc_id": "CPN12_3",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Aspirin and gastric bleeding.",
            "relevance": 2
        },
        {
            "doc_id": "CPN12_4",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Aspirin and gastric bleeding.",
            "relevance": 2
        },
        {
            "doc_id": "CPN12_5",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Aspirin and reduced gastric bleeding.",
            "relevance": 3
        },
        {
            "doc_id": "CPN12_6",
            "text": "Consistent positive results across randomized studies suggest Aspirin has a protective effect against gastric bleeding.",
            "relevance": 4
        },
        {
            "doc_id": "CPN12_7",
            "text": "Definitive clinical trials confirm Aspirin's superior ability to mitigate gastric bleeding, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN13",
    "query_type": "comparative_NOT",
    "query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
    "documents": [
        {
            "doc_id": "CPN13_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Metformin to a clear impact on lactic acidosis.",
            "relevance": 1
        },
        {
            "doc_id": "CPN13_2",
            "text": "The available literature barely mentions any direct connection between Metformin and lactic acidosis, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN13_3",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Metformin and lactic acidosis.",
            "relevance": 2
        },
        {
            "doc_id": "CPN13_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Metformin and reduced lactic acidosis.",
            "relevance": 3
        },
        {
            "doc_id": "CPN13_5",
            "text": "Consistent positive results across randomized studies suggest Metformin has a protective effect against lactic acidosis.",
            "relevance": 4
        },
        {
            "doc_id": "CPN13_6",
            "text": "Consistent positive results across randomized studies suggest Metformin has a protective effect against lactic acidosis.",
            "relevance": 4
        },
        {
            "doc_id": "CPN13_7",
            "text": "Robust meta-analyses demonstrate that Metformin significantly lowers lactic acidosis incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN14",
    "query_type": "comparative_NOT",
    "query_text": "Is Statins better than fibrates in preventing muscle cramps?",
    "documents": [
        {
            "doc_id": "CPN14_1",
            "text": "The available literature barely mentions any direct connection between Statins and muscle cramps, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN14_2",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Statins and muscle cramps.",
            "relevance": 2
        },
        {
            "doc_id": "CPN14_3",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Statins and muscle cramps.",
            "relevance": 2
        },
        {
            "doc_id": "CPN14_4",
            "text": "Certain observational trials hint that Statins could influence muscle cramps, although further validation is required.",
            "relevance": 3
        },
        {
            "doc_id": "CPN14_5",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Statins and reduced muscle cramps.",
            "relevance": 3
        },
        {
            "doc_id": "CPN14_6",
            "text": "Consistent positive results across randomized studies suggest Statins has a protective effect against muscle cramps.",
            "relevance": 4
        },
        {
            "doc_id": "CPN14_7",
            "text": "Definitive clinical trials confirm Statins's superior ability to mitigate muscle cramps, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN15",
    "query_type": "comparative_NOT",
    "query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
    "documents": [
        {
            "doc_id": "CPN15_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying SSRIs to a clear impact on weight gain.",
            "relevance": 1
        },
        {
            "doc_id": "CPN15_2",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for SSRIs and weight gain.",
            "relevance": 2
        },
        {
            "doc_id": "CPN15_3",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between SSRIs and reduced weight gain.",
            "relevance": 3
        },
        {
            "doc_id": "CPN15_4",
            "text": "Consistent positive results across randomized studies suggest SSRIs has a protective effect against weight gain.",
            "relevance": 4
        },
        {
            "doc_id": "CPN15_5",
            "text": "Well-powered trials have begun to show SSRIs's measurable benefit over alternatives in preventing weight gain.",
            "relevance": 4
        },
        {
            "doc_id": "CPN15_6",
            "text": "Definitive clinical trials confirm SSRIs's superior ability to mitigate weight gain, especially in high-risk populations.",
            "relevance": 5
        },
        {
            "doc_id": "CPN15_7",
            "text": "Robust meta-analyses demonstrate that SSRIs significantly lowers weight gain incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN16",
    "query_type": "comparative_NOT",
    "query_text": "Is PPIs better than H2 blockers in preventing kidney stones?",
    "documents": [
        {
            "doc_id": "CPN16_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying PPIs to a clear impact on kidney stones.",
            "relevance": 1
        },
        {
            "doc_id": "CPN16_2",
            "text": "Some early-stage studies raised tentative links between PPIs and kidney stones, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN16_3",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN16_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN16_5",
            "text": "Well-powered trials have begun to show PPIs's measurable benefit over alternatives in preventing kidney stones.",
            "relevance": 4
        },
        {
            "doc_id": "CPN16_6",
            "text": "Consistent positive results across randomized studies suggest PPIs has a protective effect against kidney stones.",
            "relevance": 4
        },
        {
            "doc_id": "CPN16_7",
            "text": "Robust meta-analyses demonstrate that PPIs significantly lowers kidney stones incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN17",
    "query_type": "comparative_NOT",
    "query_text": "Is Aspirin better than NSAIDs in preventing gastric bleeding?",
    "documents": [
        {
            "doc_id": "CPN17_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Aspirin to a clear impact on gastric bleeding.",
            "relevance": 1
        },
        {
            "doc_id": "CPN17_2",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Aspirin to a clear impact on gastric bleeding.",
            "relevance": 1
        },
        {
            "doc_id": "CPN17_3",
            "text": "Some early-stage studies raised tentative links between Aspirin and gastric bleeding, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN17_4",
            "text": "Some early-stage studies raised tentative links between Aspirin and gastric bleeding, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN17_5",
            "text": "Certain observational trials hint that Aspirin could influence gastric bleeding, although further validation is required.",
            "relevance": 3
        },
        {
            "doc_id": "CPN17_6",
            "text": "Well-powered trials have begun to show Aspirin's measurable benefit over alternatives in preventing gastric bleeding.",
            "relevance": 4
        },
        {
            "doc_id": "CPN17_7",
            "text": "Clinical consensus now regards Aspirin as the gold standard for preventing gastric bleeding, supported by extensive outcome data.",
            "relevance": 6
        }
    ]
},
{
    "query_id": "CPN18",
    "query_type": "comparative_NOT",
    "query_text": "Is Metformin better than SGLT2 inhibitors in preventing lactic acidosis?",
    "documents": [
        {
            "doc_id": "CPN18_1",
            "text": "The available literature barely mentions any direct connection between Metformin and lactic acidosis, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN18_2",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Metformin to a clear impact on lactic acidosis.",
            "relevance": 1
        },
        {
            "doc_id": "CPN18_3",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for Metformin and lactic acidosis.",
            "relevance": 2
        },
        {
            "doc_id": "CPN18_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Metformin and reduced lactic acidosis.",
            "relevance": 3
        },
        {
            "doc_id": "CPN18_5",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Metformin and reduced lactic acidosis.",
            "relevance": 3
        },
        {
            "doc_id": "CPN18_6",
            "text": "Well-powered trials have begun to show Metformin's measurable benefit over alternatives in preventing lactic acidosis.",
            "relevance": 4
        },
        {
            "doc_id": "CPN18_7",
            "text": "Definitive clinical trials confirm Metformin's superior ability to mitigate lactic acidosis, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN19",
    "query_type": "comparative_NOT",
    "query_text": "Is Statins better than fibrates in preventing muscle cramps?",
    "documents": [
        {
            "doc_id": "CPN19_1",
            "text": "Despite public discussions, thereu2019s little substantiated clinical evidence tying Statins to a clear impact on muscle cramps.",
            "relevance": 1
        },
        {
            "doc_id": "CPN19_2",
            "text": "Some early-stage studies raised tentative links between Statins and muscle cramps, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN19_3",
            "text": "Some early-stage studies raised tentative links between Statins and muscle cramps, but findings were statistically insignificant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN19_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between Statins and reduced muscle cramps.",
            "relevance": 3
        },
        {
            "doc_id": "CPN19_5",
            "text": "Well-powered trials have begun to show Statins's measurable benefit over alternatives in preventing muscle cramps.",
            "relevance": 4
        },
        {
            "doc_id": "CPN19_6",
            "text": "Well-powered trials have begun to show Statins's measurable benefit over alternatives in preventing muscle cramps.",
            "relevance": 4
        },
        {
            "doc_id": "CPN19_7",
            "text": "Definitive clinical trials confirm Statins's superior ability to mitigate muscle cramps, especially in high-risk populations.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN20",
    "query_type": "comparative_NOT",
    "query_text": "Is SSRIs better than SNRIs in preventing weight gain?",
    "documents": [
        {
            "doc_id": "CPN20_1",
            "text": "The available literature barely mentions any direct connection between SSRIs and weight gain, leaving a large knowledge gap.",
            "relevance": 1
        },
        {
            "doc_id": "CPN20_2",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for SSRIs and weight gain.",
            "relevance": 2
        },
        {
            "doc_id": "CPN20_3",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between SSRIs and reduced weight gain.",
            "relevance": 3
        },
        {
            "doc_id": "CPN20_4",
            "text": "Consistent positive results across randomized studies suggest SSRIs has a protective effect against weight gain.",
            "relevance": 4
        },
        {
            "doc_id": "CPN20_5",
            "text": "Definitive clinical trials confirm SSRIs's superior ability to mitigate weight gain, especially in high-risk populations.",
            "relevance": 5
        },
        {
            "doc_id": "CPN20_6",
            "text": "Definitive clinical trials confirm SSRIs's superior ability to mitigate weight gain, especially in high-risk populations.",
            "relevance": 5
        },
        {
            "doc_id": "CPN20_7",
            "text": "Robust meta-analyses demonstrate that SSRIs significantly lowers weight gain incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN10",
    "query_type": "comparative_NOT",
    "query_text": "Are SSRIs better than TCAs for achieving remission in major depressive disorder?",
    "documents": [
        {
            "doc_id": "CPN10_1",
            "text": "Some people still think TCAs are just as good, but honestly, they're not usually the first pick for depression anymore because of side effects.",
            "relevance": 1
        },
        {
            "doc_id": "CPN10_2",
            "text": "There is no compelling evidence to suggest TCAs offer superior efficacy over SSRIs in achieving remission for most cases of major depressive disorder.",
            "relevance": 1
        },
        {
            "doc_id": "CPN10_3",
            "text": "Older studies indicated TCAs could achieve remission, but their broader side effect profile often limited their practical use compared to newer options.",
            "relevance": 2
        },
        {
            "doc_id": "CPN10_4",
            "text": "A moderate number of trials show that both SSRIs and TCAs are effective antidepressants, but SSRIs generally have better tolerability.",
            "relevance": 3
        },
        {
            "doc_id": "CPN10_5",
            "text": "Retrospective analyses indicate a moderate comparability in remission rates between SSRIs and TCAs, particularly for severe depression, when tolerability is not an issue.",
            "relevance": 3
        },
        {
            "doc_id": "CPN10_6",
            "text": "Growing clinical consensus and updated guidelines strongly favor SSRIs as first-line agents due to their more favorable safety and tolerability profile, leading to higher adherence and better real-world outcomes.",
            "relevance": 4
        },
        {
            "doc_id": "CPN10_7",
            "text": "Extensive meta-analyses consistently demonstrate that while both are effective, SSRIs offer a significantly better risk-benefit profile, leading to superior overall remission rates in routine clinical practice for major depressive disorder.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN9",
    "query_type": "comparative_NOT",
    "query_text": "Are TNF inhibitors better than IL-17 inhibitors for achieving clinical remission in psoriatic arthritis?",
    "documents": [
        {
            "doc_id": "CPN9_1",
            "text": "It's a bit early to say IL-17 inhibitors are always 'better' for every psoriatic arthritis patient than TNF inhibitors; it depends on the individual.",
            "relevance": 1
        },
        {
            "doc_id": "CPN9_2",
            "text": "No definitive meta-analysis concludes that IL-17 inhibitors consistently outperform TNF inhibitors across all domains of psoriatic arthritis activity.",
            "relevance": 1
        },
        {
            "doc_id": "CPN9_3",
            "text": "Some head-to-head studies show similar efficacy, though IL-17 inhibitors might offer a slight edge in skin clearance for certain patients.",
            "relevance": 2
        },
        {
            "doc_id": "CPN9_4",
            "text": "A moderate body of research indicates that both TNF and IL-17 inhibitors are highly effective in reducing joint inflammation and skin lesions in psoriatic arthritis.",
            "relevance": 3
        },
        {
            "doc_id": "CPN9_5",
            "text": "Retrospective data suggests a moderate comparability in achieving low disease activity states between TNF and IL-17 inhibitors.",
            "relevance": 3
        },
        {
            "doc_id": "CPN9_6",
            "text": "Growing evidence points to IL-17 inhibitors potentially having a faster onset of action and better skin response in psoriatic arthritis compared to some TNF inhibitors.",
            "relevance": 4
        },
        {
            "doc_id": "CPN9_7",
            "text": "Current clinical guidelines often recommend both classes as effective, but increasing data suggests IL-17 inhibitors may offer a superior overall response in certain psoriatic arthritis phenotypes.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN8",
    "query_type": "comparative_NOT",
    "query_text": "Are oral hypoglycemic agents better than insulin for long-term glycemic control in newly diagnosed Type 2 diabetes?",
    "documents": [
        {
            "doc_id": "CPN8_1",
            "text": "Starting new Type 2 diabetics on insulin right away? That's not usually the first choice, unless things are really bad.",
            "relevance": 1
        },
        {
            "doc_id": "CPN8_2",
            "text": "There is no clinical consensus supporting the initial use of insulin over oral hypoglycemic agents for long-term glycemic control in most newly diagnosed Type 2 diabetes patients.",
            "relevance": 1
        },
        {
            "doc_id": "CPN8_3",
            "text": "Some studies indicate that while insulin can rapidly lower glucose, oral agents often provide a more sustainable, less complex initial treatment path.",
            "relevance": 2
        },
        {
            "doc_id": "CPN8_4",
            "text": "A moderate body of evidence supports the effectiveness of various oral hypoglycemic agents in achieving and maintaining good glycemic control for several years post-diagnosis.",
            "relevance": 3
        },
        {
            "doc_id": "CPN8_5",
            "text": "Retrospective analyses show that for many newly diagnosed patients, oral agents offer comparable A1c reduction to early insulin initiation with fewer side effects.",
            "relevance": 3
        },
        {
            "doc_id": "CPN8_6",
            "text": "Clinical guidelines generally recommend initiating treatment with oral agents, such as metformin, before considering insulin for most newly diagnosed Type 2 diabetics.",
            "relevance": 4
        },
        {
            "doc_id": "CPN8_7",
            "text": "Extensive randomized controlled trials and real-world data consistently demonstrate that oral hypoglycemic agents are a superior first-line therapy for long-term glycemic control in newly diagnosed Type 2 diabetes, deferring insulin initiation.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN7",
    "query_type": "comparative_NOT",
    "query_text": "Are beta-blockers better than ACE inhibitors for initial hypertension control?",
    "documents": [
        {
            "doc_id": "CPN7_1",
            "text": "Honestly, prescribing beta-blockers as a first step for simple high blood pressure isn't really the norm anymore.",
            "relevance": 1
        },
        {
            "doc_id": "CPN7_2",
            "text": "Clinical evidence does not support the routine initial use of beta-blockers over ACE inhibitors for uncomplicated hypertension management.",
            "relevance": 1
        },
        {
            "doc_id": "CPN7_3",
            "text": "While beta-blockers effectively lower blood pressure, some studies show they might be less effective than ACE inhibitors in preventing overall cardiovascular events in uncomplicated hypertension.",
            "relevance": 2
        },
        {
            "doc_id": "CPN7_4",
            "text": "A moderate number of comparative studies indicate both classes provide effective blood pressure reduction, but ACE inhibitors often have a more favorable metabolic profile.",
            "relevance": 3
        },
        {
            "doc_id": "CPN7_5",
            "text": "Retrospective analyses suggest a moderate advantage for ACE inhibitors in reducing cardiovascular mortality in hypertensive patients without specific compelling indications for beta-blockers.",
            "relevance": 3
        },
        {
            "doc_id": "CPN7_6",
            "text": "Current hypertension guidelines strongly recommend ACE inhibitors or ARBs as preferred first-line agents over beta-blockers for most patients without compelling indications.",
            "relevance": 4
        },
        {
            "doc_id": "CPN7_7",
            "text": "Extensive meta-analyses and large-scale trials unequivocally establish ACE inhibitors as superior to beta-blockers for initial hypertension control and long-term cardiovascular outcome prevention in the general hypertensive population.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN6",
    "query_type": "comparative_NOT",
    "query_text": "Are oral anticoagulants better than aspirin for preventing strokes in atrial fibrillation?",
    "documents": [
        {
            "doc_id": "CPN6_1",
            "text": "Thinking aspirin is enough for AFib stroke prevention? That's a pretty outdated idea, most docs would say.",
            "relevance": 1
        },
        {
            "doc_id": "CPN6_2",
            "text": "Current guidelines emphatically state that aspirin monotherapy is ineffective for stroke prevention in patients with atrial fibrillation.",
            "relevance": 1
        },
        {
            "doc_id": "CPN6_3",
            "text": "Early investigations into aspirin for AFib showed only a minimal, non-significant reduction in stroke risk, especially compared to true anticoagulants.",
            "relevance": 2
        },
        {
            "doc_id": "CPN6_4",
            "text": "Some observational data noted a modest association between aspirin use and reduced stroke in very low-risk AFib patients, but this isn't generally recommended.",
            "relevance": 3
        },
        {
            "doc_id": "CPN6_5",
            "text": "Clinical studies have shown that oral anticoagulants provide a moderate to significant reduction in stroke risk compared to aspirin.",
            "relevance": 3
        },
        {
            "doc_id": "CPN6_6",
            "text": "A strong body of evidence from large trials clearly demonstrates oral anticoagulants are far superior to aspirin in preventing ischemic stroke in AFib.",
            "relevance": 4
        },
        {
            "doc_id": "CPN6_7",
            "text": "Systematic reviews and comprehensive guidelines overwhelmingly support oral anticoagulants as the standard of care for effective stroke prevention in atrial fibrillation, significantly outperforming aspirin.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN5",
    "query_type": "comparative_NOT",
    "query_text": "Are biologics more effective than traditional DMARDs in achieving rheumatoid arthritis remission?",
    "documents": [
        {
            "doc_id": "CPN5_1",
            "text": "Some older studies on traditional DMARDs didn't really focus on remission, so it's tough to compare apples to apples with biologics.",
            "relevance": 1
        },
        {
            "doc_id": "CPN5_2",
            "text": "Claims of traditional DMARDs consistently achieving remission rates comparable to biologics lack substantial clinical validation.",
            "relevance": 1
        },
        {
            "doc_id": "CPN5_3",
            "text": "Initial trials showed traditional DMARDs could induce partial responses, but true, sustained remission was less frequently observed than with newer agents.",
            "relevance": 2
        },
        {
            "doc_id": "CPN5_4",
            "text": "A moderate number of studies indicate that traditional DMARDs, especially in combination, can lead to good disease control in many RA patients.",
            "relevance": 3
        },
        {
            "doc_id": "CPN5_5",
            "text": "Retrospective analyses suggest biologics provide a moderate advantage in achieving deeper and more sustained rheumatoid arthritis remission.",
            "relevance": 3
        },
        {
            "doc_id": "CPN5_6",
            "text": "Current clinical evidence strongly supports biologics offering a significantly higher likelihood of achieving sustained clinical remission in rheumatoid arthritis.",
            "relevance": 4
        },
        {
            "doc_id": "CPN5_7",
            "text": "Well-conducted randomized controlled trials and meta-analyses conclusively demonstrate the superior efficacy of biologics over traditional DMARDs in inducing and maintaining rheumatoid arthritis remission.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN4",
    "query_type": "comparative_NOT",
    "query_text": "Are SGLT2 inhibitors better than GLP-1 receptor agonists in reducing heart failure hospitalizations?",
    "documents": [
        {
            "doc_id": "CPN4_1",
            "text": "It's not really clear if GLP-1s do much for heart failure, honestly, compared to the SGLT2s.",
            "relevance": 1
        },
        {
            "doc_id": "CPN4_2",
            "text": "There is currently no definitive evidence demonstrating GLP-1 receptor agonists' superiority over SGLT2 inhibitors in reducing heart failure hospitalizations.",
            "relevance": 1
        },
        {
            "doc_id": "CPN4_3",
            "text": "Some smaller trials indicated a minor cardiovascular benefit for GLP-1s, but not specifically for heart failure hospitalizations when compared directly.",
            "relevance": 2
        },
        {
            "doc_id": "CPN4_4",
            "text": "A modest trend for heart failure benefit has been observed in some post-hoc analyses of GLP-1 trials, though SGLT2 inhibitors show a more consistent effect.",
            "relevance": 3
        },
        {
            "doc_id": "CPN4_5",
            "text": "Retrospective studies suggest a moderate advantage for SGLT2 inhibitors in preventing heart failure hospitalizations.",
            "relevance": 3
        },
        {
            "doc_id": "CPN4_6",
            "text": "Recent large-scale trials overwhelmingly confirm that SGLT2 inhibitors significantly reduce heart failure hospitalizations across various patient populations.",
            "relevance": 4
        },
        {
            "doc_id": "CPN4_7",
            "text": "Consolidated meta-analyses unequivocally establish SGLT2 inhibitors as highly effective in reducing heart failure hospitalizations, surpassing GLP-1 receptor agonists in this specific outcome.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN3",
    "query_type": "comparative_NOT",
    "query_text": "Is acetaminophen better than NSAIDs for long-term chronic pain management?",
    "documents": [
        {
            "doc_id": "CPN3_1",
            "text": "Many people just assume acetaminophen is safer long-term, but that's not always true for chronic pain.",
            "relevance": 1
        },
        {
            "doc_id": "CPN3_2",
            "text": "Evidence suggesting acetaminophen's widespread superiority over NSAIDs for all types of chronic pain management is unsubstantiated.",
            "relevance": 1
        },
        {
            "doc_id": "CPN3_3",
            "text": "Some studies indicate acetaminophen can provide mild relief for specific chronic pain conditions, though it's often less potent than NSAIDs.",
            "relevance": 2
        },
        {
            "doc_id": "CPN3_4",
            "text": "A moderate body of evidence supports acetaminophen's role in managing chronic pain, especially where NSAID side effects are a concern.",
            "relevance": 3
        },
        {
            "doc_id": "CPN3_5",
            "text": "Retrospective reviews show a comparable efficacy for acetaminophen and some NSAIDs in reducing certain chronic pain scores.",
            "relevance": 3
        },
        {
            "doc_id": "CPN3_6",
            "text": "New clinical guidelines suggest acetaminophen as a viable first-line option for some chronic non-inflammatory pain, often preferred due to its safety profile.",
            "relevance": 4
        },
        {
            "doc_id": "CPN3_7",
            "text": "Systematic reviews conclude that while NSAIDs can be effective, acetaminophen offers a significantly safer long-term profile for chronic pain without substantial loss of efficacy in many cases.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN2",
    "query_type": "comparative_NOT",
    "query_text": "Are statins more effective than fibrates in preventing major cardiovascular events?",
    "documents": [
        {
            "doc_id": "CPN2_1",
            "text": "Some doctors still wonder if fibrates are really inferior to statins for preventing heart issues; the data's a bit fuzzy.",
            "relevance": 1
        },
        {
            "doc_id": "CPN2_2",
            "text": "Despite ongoing debate, no direct, large-scale studies have shown fibrates to be superior to statins in primary cardiovascular event prevention.",
            "relevance": 1
        },
        {
            "doc_id": "CPN2_3",
            "text": "Early, smaller trials hinted at a mild benefit for fibrates in certain lipid profiles, but their overall impact on cardiovascular events compared to statins wasn't significant.",
            "relevance": 2
        },
        {
            "doc_id": "CPN2_4",
            "text": "Observational data suggests a modest reduction in some cardiovascular markers with fibrates, though less pronounced than with statins.",
            "relevance": 3
        },
        {
            "doc_id": "CPN2_5",
            "text": "Retrospective studies have noted a moderate trend favoring statins in reducing overall cardiovascular event rates.",
            "relevance": 3
        },
        {
            "doc_id": "CPN2_6",
            "text": "Growing evidence from head-to-head trials indicates that statins offer a more substantial reduction in major cardiovascular events compared to fibrates.",
            "relevance": 4
        },
        {
            "doc_id": "CPN2_7",
            "text": "Large-scale meta-analyses consistently confirm statins' superior efficacy over fibrates in preventing cardiovascular morbidity and mortality.",
            "relevance": 5
        }
    ]
},
{
    "query_id": "CPN1",
    "query_type": "comparative_NOT",
    "query_text": "Is PPIs better than H2 blockers in preventing kidney stones?",
    "documents": [
        {
            "doc_id": "CPN1_1",
            "text": "Despite public discussions, theres little substantiated clinical evidence tying PPIs to a clear impact on kidney stones.",
            "relevance": 1
        },
        {
            "doc_id": "CPN1_2",
            "text": "Frankly, solid evidence linking PPIs to kidney stone prevention simply isn't there.",
            "relevance": 1
        },
        {
            "doc_id": "CPN1_3",
            "text": "Weak associations have appeared in small sample studies, yet reproducibility has been lacking for PPIs and kidney stones.",
            "relevance": 2
        },
        {
            "doc_id": "CPN1_4",
            "text": "A moderate trend appeared across retrospective studies, suggesting a possible link between PPIs and reduced kidney stones.",
            "relevance": 3
        },
        {
            "doc_id": "CPN1_5",
            "text": "Several retrospective analyses have indicated a moderate relationship, suggesting PPIs might play a role in reducing kidney stone occurrence.",
            "relevance": 3
        },
        {
            "doc_id": "CPN1_6",
            "text": "Well-powered trials have begun to show PPIs' measurable benefit over alternatives in preventing kidney stones.",
            "relevance": 4
        },
        {
            "doc_id": "CPN1_7",
            "text": "Robust meta-analyses demonstrate that PPIs significantly lowers kidney stones incidence compared to its alternatives.",
            "relevance": 5
        }
    ]
},
    {
        "query_id": "CPN11",
        "query_type": "comparative_NOT",
        "query_text": "Is metformin better than sulfonylureas for weight management in Type 2 diabetes?",
        "documents": [
            {
                "doc_id": "CPN11_1",
                "text": "Honestly, sulfonylureas are kinda known for making you gain weight, unlike metformin.",
                "relevance": 1
            },
            {
                "doc_id": "CPN11_2",
                "text": "Clinical evidence consistently indicates that sulfonylureas are associated with weight gain, whereas metformin tends to be weight-neutral or facilitate modest weight loss.",
                "relevance": 1
            },
            {
                "doc_id": "CPN11_3",
                "text": "Some studies show sulfonylureas can effectively lower blood sugar, but often with the undesirable side effect of increased body weight.",
                "relevance": 2
            },
            {
                "doc_id": "CPN11_4",
                "text": "A moderate number of comparative studies demonstrate metformin's advantage in weight management, even if both drugs control blood sugar.",
                "relevance": 3
            },
            {
                "doc_id": "CPN11_5",
                "text": "Retrospective data suggests a modest trend for better weight outcomes with metformin compared to sulfonylureas.",
                "relevance": 3
            },
            {
                "doc_id": "CPN11_6",
                "text": "Current treatment guidelines strongly recommend metformin as a first-line agent, partly due to its favorable weight profile, especially when compared to sulfonylureas.",
                "relevance": 4
            },
            {
                "doc_id": "CPN11_7",
                "text": "Extensive meta-analyses and real-world studies conclusively show metformin's superior benefits for weight management and overall metabolic health compared to sulfonylureas in Type 2 diabetes.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN12",
        "query_type": "comparative_NOT",
        "query_text": "Are biologics better than methotrexate for preventing joint damage in early rheumatoid arthritis?",
        "documents": [
            {
                "doc_id": "CPN12_1",
                "text": "Some experts argue that while methotrexate is good, it doesn't always completely stop joint damage in early RA like biologics might.",
                "relevance": 1
            },
            {
                "doc_id": "CPN12_2",
                "text": "Despite its efficacy, methotrexate monotherapy does not consistently achieve the same degree of joint damage prevention as biologics in early rheumatoid arthritis.",
                "relevance": 1
            },
            {
                "doc_id": "CPN12_3",
                "text": "Early studies suggested methotrexate significantly slowed joint progression, but imaging shows some patients still experience subtle damage over time.",
                "relevance": 2
            },
            {
                "doc_id": "CPN12_4",
                "text": "A moderate amount of evidence indicates that combined therapy (methotrexate plus biologics) is superior to methotrexate alone for preventing joint damage.",
                "relevance": 3
            },
            {
                "doc_id": "CPN12_5",
                "text": "Retrospective analyses indicate a moderate advantage for biologics in preserving joint integrity more effectively than methotrexate.",
                "relevance": 3
            },
            {
                "doc_id": "CPN12_6",
                "text": "Long-term follow-up studies increasingly show biologics offer a more robust and consistent prevention of radiographic joint damage in early RA.",
                "relevance": 4
            },
            {
                "doc_id": "CPN12_7",
                "text": "Comprehensive clinical trials and systematic reviews definitively demonstrate the superior efficacy of biologics over methotrexate monotherapy in halting joint damage progression in early rheumatoid arthritis.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN13",
        "query_type": "comparative_NOT",
        "query_text": "Is high-dose atorvastatin better than moderate-dose simvastatin for secondary stroke prevention?",
        "documents": [
            {
                "doc_id": "CPN13_1",
                "text": "Some docs think simvastatin at moderate doses is just fine, but the really strong evidence pushes for high-dose atorvastatin.",
                "relevance": 1
            },
            {
                "doc_id": "CPN13_2",
                "text": "There is limited evidence to suggest that moderate-dose simvastatin provides comparable stroke prevention to high-dose atorvastatin in secondary prevention.",
                "relevance": 1
            },
            {
                "doc_id": "CPN13_3",
                "text": "Small-scale studies have shown some lipid-lowering effects with moderate-dose simvastatin, but its specific impact on secondary stroke prevention isn't as well-defined.",
                "relevance": 2
            },
            {
                "doc_id": "CPN13_4",
                "text": "A moderate number of trials have indicated that intensive statin therapy, including high-dose atorvastatin, yields better outcomes for secondary cardiovascular events.",
                "relevance": 3
            },
            {
                "doc_id": "CPN13_5",
                "text": "Retrospective studies suggest a moderate trend favoring high-dose atorvastatin in reducing recurrent stroke risk.",
                "relevance": 3
            },
            {
                "doc_id": "CPN13_6",
                "text": "Leading clinical guidelines advocate for high-intensity statin therapy, specifically citing high-dose atorvastatin, for superior secondary stroke prevention.",
                "relevance": 4
            },
            {
                "doc_id": "CPN13_7",
                "text": "Robust randomized controlled trials and meta-analyses conclusively demonstrate that high-dose atorvastatin provides significantly superior secondary stroke prevention compared to moderate-dose simvastatin.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN14",
        "query_type": "comparative_NOT",
        "query_text": "Is paracetamol better than ibuprofen for fever reduction in children?",
        "documents": [
            {
                "doc_id": "CPN14_1",
                "text": "Some parents just stick to paracetamol for fever, but ibuprofen is often just as good, if not better, for some kids.",
                "relevance": 1
            },
            {
                "doc_id": "CPN14_2",
                "text": "No clinical evidence suggests paracetamol universally outperforms ibuprofen in the rapidity or magnitude of fever reduction in children.",
                "relevance": 1
            },
            {
                "doc_id": "CPN14_3",
                "text": "Initial trials indicated both drugs effectively reduce fever, with slight differences in onset or duration depending on the specific study.",
                "relevance": 2
            },
            {
                "doc_id": "CPN14_4",
                "text": "A moderate number of studies show comparable efficacy between paracetamol and ibuprofen for fever reduction in pediatric populations.",
                "relevance": 3
            },
            {
                "doc_id": "CPN14_5",
                "text": "Retrospective data suggests a moderate similarity in temperature-lowering effects when comparing ibuprofen and paracetamol.",
                "relevance": 3
            },
            {
                "doc_id": "CPN14_6",
                "text": "Recent systematic reviews indicate ibuprofen may provide a slightly more sustained antipyretic effect than paracetamol in children.",
                "relevance": 4
            },
            {
                "doc_id": "CPN14_7",
                "text": "Comprehensive meta-analyses demonstrate that ibuprofen is often more effective and has a longer duration of action than paracetamol for fever reduction in children.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN15",
        "query_type": "comparative_NOT",
        "query_text": "Are long-acting insulins better than intermediate-acting insulins for basal control in Type 1 diabetes?",
        "documents": [
            {
                "doc_id": "CPN15_1",
                "text": "Some diabetics just prefer NPH, but modern long-acting insulins are usually a lot more stable.",
                "relevance": 1
            },
            {
                "doc_id": "CPN15_2",
                "text": "Historical data on intermediate-acting insulins does not demonstrate superior or even equivalent basal control compared to modern long-acting analogs.",
                "relevance": 1
            },
            {
                "doc_id": "CPN15_3",
                "text": "Early research on intermediate-acting insulins showed variable absorption and peak action, often leading to less predictable glucose levels.",
                "relevance": 2
            },
            {
                "doc_id": "CPN15_4",
                "text": "A moderate number of clinical trials indicate long-acting insulins provide a more stable and consistent basal glucose profile.",
                "relevance": 3
            },
            {
                "doc_id": "CPN15_5",
                "text": "Retrospective studies suggest a moderate reduction in nocturnal hypoglycemia with long-acting insulins compared to intermediate-acting ones.",
                "relevance": 3
            },
            {
                "doc_id": "CPN15_6",
                "text": "Current clinical guidelines overwhelmingly recommend long-acting insulin analogs due to their flatter profiles and reduced risk of hypoglycemia for basal control.",
                "relevance": 4
            },
            {
                "doc_id": "CPN15_7",
                "text": "Extensive randomized controlled trials and real-world evidence conclusively show long-acting insulins provide superior, more predictable basal glycemic control with a significantly lower risk of nocturnal hypoglycemia in Type 1 diabetes.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN16",
        "query_type": "comparative_NOT",
        "query_text": "Is oral penicillin better than amoxicillin for treating strep throat?",
        "documents": [
            {
                "doc_id": "CPN16_1",
                "text": "Honestly, people often think any penicillin works for strep, but amoxicillin is pretty much the go-to nowadays.",
                "relevance": 1
            },
            {
                "doc_id": "CPN16_2",
                "text": "No robust clinical data substantiates superior efficacy of oral penicillin V over amoxicillin for uncomplicated streptococcal pharyngitis.",
                "relevance": 1
            },
            {
                "doc_id": "CPN16_3",
                "text": "Both antibiotics are effective, though amoxicillin's better taste and once-daily dosing might lead to better patient adherence.",
                "relevance": 2
            },
            {
                "doc_id": "CPN16_4",
                "text": "A moderate body of evidence indicates comparable clinical cure rates for both penicillin and amoxicillin in treating strep throat.",
                "relevance": 3
            },
            {
                "doc_id": "CPN16_5",
                "text": "Retrospective analyses suggest a moderate similarity in bacterial eradication rates between penicillin and amoxicillin for Group A Strep.",
                "relevance": 3
            },
            {
                "doc_id": "CPN16_6",
                "text": "Current infectious disease guidelines often recommend amoxicillin as the preferred agent for strep throat due to its favorable pharmacokinetics and dosing schedule.",
                "relevance": 4
            },
            {
                "doc_id": "CPN16_7",
                "text": "Systematic reviews and clinical trials consistently demonstrate that amoxicillin offers superior adherence and convenience without compromising efficacy, making it effectively better than oral penicillin V for most strep throat cases.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN17",
        "query_type": "comparative_NOT",
        "query_text": "Are topical corticosteroids better than oral antihistamines for acute urticaria relief?",
        "documents": [
            {
                "doc_id": "CPN17_1",
                "text": "Using topical creams for hives doesn't really do much; you need something systemic.",
                "relevance": 1
            },
            {
                "doc_id": "CPN17_2",
                "text": "Topical corticosteroids have demonstrated minimal efficacy for the symptomatic relief of acute urticaria, unlike oral antihistamines.",
                "relevance": 1
            },
            {
                "doc_id": "CPN17_3",
                "text": "Some studies showed slight localized anti-inflammatory effects from topicals, but they don't address the widespread itch of hives effectively.",
                "relevance": 2
            },
            {
                "doc_id": "CPN17_4",
                "text": "A moderate amount of evidence confirms oral antihistamines significantly reduce itching and wheal formation in acute urticaria.",
                "relevance": 3
            },
            {
                "doc_id": "CPN17_5",
                "text": "Retrospective reviews indicate oral antihistamines provide a moderate but clear benefit in symptom control for acute urticaria.",
                "relevance": 3
            },
            {
                "doc_id": "CPN17_6",
                "text": "Clinical guidelines universally recommend oral antihistamines as the primary pharmacological treatment for acute urticaria due to their systemic effect.",
                "relevance": 4
            },
            {
                "doc_id": "CPN17_7",
                "text": "Comprehensive meta-analyses definitively show that oral antihistamines are vastly superior to topical corticosteroids for rapid and complete symptomatic relief in acute urticaria.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN18",
        "query_type": "comparative_NOT",
        "query_text": "Are direct oral anticoagulants better than warfarin for reducing bleeding risk in atrial fibrillation?",
        "documents": [
            {
                "doc_id": "CPN18_1",
                "text": "Sometimes people think warfarin's bleeding risk is overblown, but it's genuinely higher than with the newer drugs.",
                "relevance": 1
            },
            {
                "doc_id": "CPN18_2",
                "text": "Warfarin's narrow therapeutic index and numerous drug interactions contribute to a higher inherent bleeding risk compared to direct oral anticoagulants.",
                "relevance": 1
            },
            {
                "doc_id": "CPN18_3",
                "text": "Early trials on direct oral anticoagulants indicated a trend towards lower intracranial bleeding, though overall major bleeding rates were sometimes similar.",
                "relevance": 2
            },
            {
                "doc_id": "CPN18_4",
                "text": "A moderate number of studies show direct oral anticoagulants offer a reduced risk of major bleeding, especially intracranial hemorrhage, compared to warfarin.",
                "relevance": 3
            },
            {
                "doc_id": "CPN18_5",
                "text": "Retrospective analyses suggest a moderate but consistent benefit of DOACs in reducing gastrointestinal bleeding compared to warfarin.",
                "relevance": 3
            },
            {
                "doc_id": "CPN18_6",
                "text": "Current clinical practice guidelines increasingly favor direct oral anticoagulants for their improved safety profile and lower bleeding rates, especially for serious bleeding.",
                "relevance": 4
            },
            {
                "doc_id": "CPN18_7",
                "text": "Large-scale randomized controlled trials and comprehensive meta-analyses unequivocally demonstrate that direct oral anticoagulants significantly reduce the risk of major and intracranial bleeding compared to warfarin in atrial fibrillation.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN19",
        "query_type": "comparative_NOT",
        "query_text": "Is varenicline better than bupropion for smoking cessation success rates?",
        "documents": [
            {
                "doc_id": "CPN19_1",
                "text": "Some folks find bupropion works well, but for many, it's just not as strong as varenicline for quitting smoking.",
                "relevance": 1
            },
            {
                "doc_id": "CPN19_2",
                "text": "While effective, bupropion does not consistently achieve the same high abstinence rates as varenicline in comprehensive smoking cessation programs.",
                "relevance": 1
            },
            {
                "doc_id": "CPN19_3",
                "text": "Initial trials showed bupropion offered significant benefits over placebo, but head-to-head comparisons with varenicline sometimes indicated less pronounced effects.",
                "relevance": 2
            },
            {
                "doc_id": "CPN19_4",
                "text": "A moderate number of studies suggest varenicline provides a greater chance of sustained abstinence from smoking.",
                "relevance": 3
            },
            {
                "doc_id": "CPN19_5",
                "text": "Retrospective analyses show a moderate trend favoring varenicline in achieving higher rates of smoking cessation at 6 and 12 months.",
                "relevance": 3
            },
            {
                "doc_id": "CPN19_6",
                "text": "Current guidelines consistently rank varenicline among the most effective pharmacotherapies for smoking cessation, often above bupropion.",
                "relevance": 4
            },
            {
                "doc_id": "CPN19_7",
                "text": "Comprehensive meta-analyses and network meta-analyses unequivocally demonstrate that varenicline achieves superior long-term smoking cessation rates compared to bupropion.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN20",
        "query_type": "comparative_NOT",
        "query_text": "Are ACE inhibitors better than diuretics for preventing new-onset diabetes in hypertension?",
        "documents": [
            {
                "doc_id": "CPN20_1",
                "text": "Honestly, diuretics can make blood sugar worse for some people, so they're not always the best choice for blood pressure if you're worried about diabetes.",
                "relevance": 1
            },
            {
                "doc_id": "CPN20_2",
                "text": "Numerous studies have demonstrated that certain diuretics, particularly thiazides, are associated with an increased risk of new-onset diabetes.",
                "relevance": 1
            },
            {
                "doc_id": "CPN20_3",
                "text": "Some older trials hinted that diuretics could raise blood glucose slightly, but the full picture on new-onset diabetes wasn't clear.",
                "relevance": 2
            },
            {
                "doc_id": "CPN20_4",
                "text": "A moderate body of evidence suggests that ACE inhibitors have a neutral or even protective effect on glucose metabolism in hypertensive patients.",
                "relevance": 3
            },
            {
                "doc_id": "CPN20_5",
                "text": "Retrospective analyses indicate a moderate reduction in the risk of developing diabetes when using ACE inhibitors compared to diuretics.",
                "relevance": 3
            },
            {
                "doc_id": "CPN20_6",
                "text": "Major randomized controlled trials have shown ACE inhibitors significantly reduce the incidence of new-onset Type 2 diabetes in hypertensive populations compared to diuretics.",
                "relevance": 4
            },
            {
                "doc_id": "CPN20_7",
                "text": "Robust meta-analyses and large-scale outcome trials unequivocally demonstrate that ACE inhibitors are superior to diuretics in preventing new-onset diabetes in patients with hypertension.",
                "relevance": 5
            }
        ]
    },

    {
        "query_id": "CPN31",
        "query_type": "comparative_NOT",
        "query_text": "Is rosuvastatin better than simvastatin for achieving very low LDL-C levels?",
        "documents": [
            {
                "doc_id": "CPN31_1",
                "text": "Some folks think all statins are the same, but for super low cholesterol, rosuvastatin often has an edge.",
                "relevance": 1
            },
            {
                "doc_id": "CPN31_2",
                "text": "While simvastatin is effective, its potency for achieving very low LDL-C targets is not consistently comparable to rosuvastatin.",
                "relevance": 1
            },
            {
                "doc_id": "CPN31_3",
                "text": "Early dose-response studies indicated rosuvastatin achieved greater LDL-C reductions at comparable or lower doses than simvastatin.",
                "relevance": 2
            },
            {
                "doc_id": "CPN31_4",
                "text": "A moderate number of comparative trials demonstrate rosuvastatin's superior efficacy in achieving aggressive LDL-C lowering targets.",
                "relevance": 3
            },
            {
                "doc_id": "CPN31_5",
                "text": "Retrospective analyses suggest a moderate advantage for rosuvastatin in reaching very low LDL-C goals in high-risk patients.",
                "relevance": 3
            },
            {
                "doc_id": "CPN31_6",
                "text": "Current lipid guidelines often recommend rosuvastatin as a preferred high-intensity statin for achieving maximal LDL-C reduction.",
                "relevance": 4
            },
            {
                "doc_id": "CPN31_7",
                "text": "Comprehensive meta-analyses and head-to-head trials conclusively show rosuvastatin's superior potency over simvastatin in achieving very low LDL-C levels for cardiovascular risk reduction.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN32",
        "query_type": "comparative_NOT",
        "query_text": "Are SGLT2 inhibitors better than DPP-4 inhibitors for cardiovascular protection in Type 2 diabetes?",
        "documents": [
            {
                "doc_id": "CPN32_1",
                "text": "Don't get me wrong, DPP-4 inhibitors are fine for blood sugar, but they don't do much for the heart like SGLT2s.",
                "relevance": 1
            },
            {
                "doc_id": "CPN32_2",
                "text": "Cardiovascular outcome trials have not demonstrated significant cardiovascular protective effects for DPP-4 inhibitors, unlike SGLT2 inhibitors.",
                "relevance": 1
            },
            {
                "doc_id": "CPN32_3",
                "text": "Some studies showed DPP-4 inhibitors are glucose-lowering, but their impact on reducing major cardiovascular events was often neutral.",
                "relevance": 2
            },
            {
                "doc_id": "CPN32_4",
                "text": "A moderate body of evidence confirms SGLT2 inhibitors significantly reduce the risk of major adverse cardiovascular events in diabetic patients.",
                "relevance": 3
            },
            {
                "doc_id": "CPN32_5",
                "text": "Retrospective analyses indicate a moderate but clear cardiovascular benefit associated with SGLT2 inhibitor use.",
                "relevance": 3
            },
            {
                "doc_id": "CPN32_6",
                "text": "Leading diabetes and cardiology guidelines now strongly recommend SGLT2 inhibitors for Type 2 diabetics with established cardiovascular disease or high risk.",
                "relevance": 4
            },
            {
                "doc_id": "CPN32_7",
                "text": "Large-scale cardiovascular outcome trials and meta-analyses unequivocally establish SGLT2 inhibitors' superior efficacy over DPP-4 inhibitors in providing cardiovascular protection for Type 2 diabetics.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN33",
        "query_type": "comparative_NOT",
        "query_text": "Is omalizumab better than standard antihistamines for chronic spontaneous urticaria with inadequate response?",
        "documents": [
            {
                "doc_id": "CPN33_1",
                "text": "Just trying more antihistamines when they aren't working is a waste; you need something stronger for severe hives.",
                "relevance": 1
            },
            {
                "doc_id": "CPN33_2",
                "text": "Increasing doses of standard antihistamines often fails to control chronic spontaneous urticaria in patients with inadequate response.",
                "relevance": 1
            },
            {
                "doc_id": "CPN33_3",
                "text": "Some patients might get minor relief from higher antihistamine doses, but complete control is rarely achieved.",
                "relevance": 2
            },
            {
                "doc_id": "CPN33_4",
                "text": "A moderate number of studies indicate omalizumab significantly reduces symptoms and improves quality of life in refractory chronic spontaneous urticaria.",
                "relevance": 3
            },
            {
                "doc_id": "CPN33_5",
                "text": "Retrospective data suggests a moderate but consistent benefit of omalizumab in controlling difficult-to-treat chronic spontaneous urticaria.",
                "relevance": 3
            },
            {
                "doc_id": "CPN33_6",
                "text": "Clinical guidelines recommend omalizumab as a highly effective second-line therapy for chronic spontaneous urticaria unresponsive to antihistamines.",
                "relevance": 4
            },
            {
                "doc_id": "CPN33_7",
                "text": "Randomized controlled trials and meta-analyses conclusively demonstrate omalizumab's superior efficacy over continued standard antihistamine therapy in achieving complete symptom control in chronic spontaneous urticaria with inadequate response.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN34",
        "query_type": "comparative_NOT",
        "query_text": "Are biologics better than conventional systemic agents for reducing psoriasis severity (PASI score) in moderate-to-severe plaque psoriasis?",
        "documents": [
            {
                "doc_id": "CPN34_1",
                "text": "Don't just stick with old meds; for really bad psoriasis, biologics are a game-changer, plain and simple.",
                "relevance": 1
            },
            {
                "doc_id": "CPN34_2",
                "text": "Conventional systemic agents do not consistently achieve the same magnitude of PASI score reduction as biologics in moderate-to-severe plaque psoriasis.",
                "relevance": 1
            },
            {
                "doc_id": "CPN34_3",
                "text": "While conventional agents can improve psoriasis, many patients experience suboptimal responses or significant side effects limiting their long-term use.",
                "relevance": 2
            },
            {
                "doc_id": "CPN34_4",
                "text": "A moderate body of evidence indicates biologics achieve high rates of PASI 75 and PASI 90 responses in a significant proportion of patients.",
                "relevance": 3
            },
            {
                "doc_id": "CPN34_5",
                "text": "Retrospective analyses suggest a moderate advantage for biologics in achieving and maintaining very low PASI scores.",
                "relevance": 3
            },
            {
                "doc_id": "CPN34_6",
                "text": "Leading dermatology guidelines prioritize biologics for moderate-to-severe plaque psoriasis due to their superior efficacy and safety profile.",
                "relevance": 4
            },
            {
                "doc_id": "CPN34_7",
                "text": "Extensive randomized controlled trials and network meta-analyses unequivocally demonstrate the superior efficacy of biologics over conventional systemic agents in achieving robust and sustained PASI score reductions in moderate-to-severe plaque psoriasis.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN35",
        "query_type": "comparative_NOT",
        "query_text": "Is selective COX-2 inhibitors better than non-selective NSAIDs for reducing gastrointestinal adverse events?",
        "documents": [
            {
                "doc_id": "CPN35_1",
                "text": "It's a myth that all pain meds upset your stomach equally; some are definitely easier on it.",
                "relevance": 1
            },
            {
                "doc_id": "CPN35_2",
                "text": "Non-selective NSAIDs are strongly associated with a higher incidence of serious gastrointestinal adverse events compared to selective COX-2 inhibitors.",
                "relevance": 1
            },
            {
                "doc_id": "CPN35_3",
                "text": "While both types can cause GI issues, non-selective NSAIDs more frequently lead to ulcers and bleeding due to their mechanism of action.",
                "relevance": 2
            },
            {
                "doc_id": "CPN35_4",
                "text": "A moderate number of studies indicate COX-2 inhibitors offer a reduced risk of upper gastrointestinal complications.",
                "relevance": 3
            },
            {
                "doc_id": "CPN35_5",
                "text": "Retrospective analyses suggest a moderate but consistent benefit of selective COX-2 inhibitors in lowering GI bleed rates.",
                "relevance": 3
            },
            {
                "doc_id": "CPN35_6",
                "text": "Clinical guidelines recommend selective COX-2 inhibitors for patients requiring NSAIDs who are at high risk for gastrointestinal adverse events.",
                "relevance": 4
            },
            {
                "doc_id": "CPN35_7",
                "text": "Large-scale randomized controlled trials and comprehensive meta-analyses conclusively demonstrate the superior gastrointestinal safety profile of selective COX-2 inhibitors over non-selective NSAIDs.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN36",
        "query_type": "comparative_NOT",
        "query_text": "Are topical calcineurin inhibitors better than low-potency topical corticosteroids for long-term facial eczema management in children?",
        "documents": [
            {
                "doc_id": "CPN36_1",
                "text": "You really shouldn't use strong steroid creams on kids' faces for a long time; it can mess up their skin.",
                "relevance": 1
            },
            {
                "doc_id": "CPN36_2",
                "text": "Prolonged use of even low-potency topical corticosteroids on facial skin in children carries risks of atrophy and other adverse effects.",
                "relevance": 1
            },
            {
                "doc_id": "CPN36_3",
                "text": "While low-potency steroids offer good initial control, concern for side effects limits their continuous application on delicate facial skin.",
                "relevance": 2
            },
            {
                "doc_id": "CPN36_4",
                "text": "A moderate body of evidence indicates topical calcineurin inhibitors provide effective and safe long-term control of facial eczema without steroid-related side effects.",
                "relevance": 3
            },
            {
                "doc_id": "CPN36_5",
                "text": "Retrospective data suggests a moderate advantage for topical calcineurin inhibitors in maintaining remission on facial areas.",
                "relevance": 3
            },
            {
                "doc_id": "CPN36_6",
                "text": "Dermatology guidelines recommend topical calcineurin inhibitors as preferred first-line, long-term options for facial eczema, especially in children, due to their safety profile.",
                "relevance": 4
            },
            {
                "doc_id": "CPN36_7",
                "text": "Comprehensive meta-analyses and clinical trials definitively establish topical calcineurin inhibitors' superior safety and comparable efficacy for long-term facial eczema management in children compared to topical corticosteroids, avoiding steroid-related adverse events.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN37",
        "query_type": "comparative_NOT",
        "query_text": "Are non-pharmacological interventions better than benzodiazepines for long-term generalized anxiety disorder management?",
        "documents": [
            {
                "doc_id": "CPN37_1",
                "text": "Just popping benzos for anxiety forever isn't a real solution; it's a short-term fix with problems.",
                "relevance": 1
            },
            {
                "doc_id": "CPN37_2",
                "text": "Long-term benzodiazepine monotherapy for GAD is associated with risks of dependence, tolerance, and cognitive impairment, making it unsuitable for sustained management.",
                "relevance": 1
            },
            {
                "doc_id": "CPN37_3",
                "text": "While benzodiazepines offer rapid anxiolysis, their benefits often wane with chronic use, and discontinuation can be challenging.",
                "relevance": 2
            },
            {
                "doc_id": "CPN37_4",
                "text": "A moderate body of evidence indicates that non-pharmacological interventions, such as CBT and mindfulness, provide lasting improvements in anxiety symptoms.",
                "relevance": 3
            },
            {
                "doc_id": "CPN37_5",
                "text": "Retrospective studies suggest a moderate advantage for non-pharmacological approaches in promoting sustained remission and preventing relapse in GAD.",
                "relevance": 3
            },
            {
                "doc_id": "CPN37_6",
                "text": "Leading clinical guidelines consistently recommend non-pharmacological strategies as core components of long-term GAD management due to their durable effects and lack of dependence.",
                "relevance": 4
            },
            {
                "doc_id": "CPN37_7",
                "text": "Comprehensive meta-analyses and long-term follow-up studies unequivocally demonstrate that non-pharmacological interventions are superior to benzodiazepines for achieving sustained remission and preventing relapse in generalized anxiety disorder.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN38",
        "query_type": "comparative_NOT",
        "query_text": "Is rituximab better than cyclophosphamide for treating severe active lupus nephritis?",
        "documents": [
            {
                "doc_id": "CPN38_1",
                "text": "Some doctors still start with cyclophosphamide, but rituximab is increasingly seen as a better choice for severe lupus kidney problems.",
                "relevance": 1
            },
            {
                "doc_id": "CPN38_2",
                "text": "While cyclophosphamide is effective, its significant toxicity profile limits its long-term use and makes alternatives highly desirable.",
                "relevance": 1
            },
            {
                "doc_id": "CPN38_3",
                "text": "Initial trials showed cyclophosphamide induced remission, but often with high rates of adverse events, including infections and infertility.",
                "relevance": 2
            },
            {
                "doc_id": "CPN38_4",
                "text": "A moderate number of studies indicate rituximab, particularly when combined, achieves good renal response rates with a more favorable safety profile.",
                "relevance": 3
            },
            {
                "doc_id": "CPN38_5",
                "text": "Retrospective analyses suggest a moderate comparability in renal remission rates, with rituximab often preferred for its reduced cumulative toxicity.",
                "relevance": 3
            },
            {
                "doc_id": "CPN38_6",
                "text": "Recent evidence supports rituximab as an effective alternative or add-on therapy for severe lupus nephritis, with improved tolerability compared to cyclophosphamide.",
                "relevance": 4
            },
            {
                "doc_id": "CPN38_7",
                "text": "Randomized controlled trials and systematic reviews increasingly demonstrate rituximab's superior long-term safety profile and comparable efficacy to cyclophosphamide in achieving sustained renal response in severe active lupus nephritis.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN39",
        "query_type": "comparative_NOT",
        "query_text": "Are oral antibiotics better than local debridement alone for chronic diabetic foot ulcers?",
        "documents": [
            {
                "doc_id": "CPN39_1",
                "text": "Just cleaning a diabetic foot ulcer isn't enough if there's infection; you absolutely need antibiotics sometimes.",
                "relevance": 1
            },
            {
                "doc_id": "CPN39_2",
                "text": "Local debridement alone is insufficient for treating infected chronic diabetic foot ulcers, necessitating systemic antibiotic therapy.",
                "relevance": 1
            },
            {
                "doc_id": "CPN39_3",
                "text": "While debridement removes necrotic tissue, it does not address underlying infection which can lead to rapid deterioration.",
                "relevance": 2
            },
            {
                "doc_id": "CPN39_4",
                "text": "A moderate body of evidence indicates that oral antibiotics, alongside debridement, significantly improve wound healing rates in infected diabetic foot ulcers.",
                "relevance": 3
            },
            {
                "doc_id": "CPN39_5",
                "text": "Retrospective analyses suggest a moderate but clear benefit of combining antibiotics with local care to prevent osteomyelitis and amputations.",
                "relevance": 3
            },
            {
                "doc_id": "CPN39_6",
                "text": "Clinical guidelines universally recommend systemic antibiotics for infected diabetic foot ulcers, in addition to proper wound care and debridement.",
                "relevance": 4
            },
            {
                "doc_id": "CPN39_7",
                "text": "Extensive clinical trials and meta-analyses conclusively demonstrate that oral antibiotics, when appropriate, are vastly superior to local debridement alone for successful treatment and prevention of complications in infected chronic diabetic foot ulcers.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN40",
        "query_type": "comparative_NOT",
        "query_text": "Is high-flow nasal cannula better than conventional oxygen therapy for acute hypoxemic respiratory failure?",
        "documents": [
            {
                "doc_id": "CPN40_1",
                "text": "Just regular oxygen for severe breathing issues? Nah, you probably need something with more oomph like high-flow.",
                "relevance": 1
            },
            {
                "doc_id": "CPN40_2",
                "text": "Conventional oxygen therapy often fails to provide adequate ventilatory support for patients with acute hypoxemic respiratory failure.",
                "relevance": 1
            },
            {
                "doc_id": "CPN40_3",
                "text": "While useful for mild hypoxemia, conventional oxygen delivery methods don't offer the physiological benefits of high flow (e.g., dead space washout, positive pressure).",
                "relevance": 2
            },
            {
                "doc_id": "CPN40_4",
                "text": "A moderate number of studies indicate high-flow nasal cannula significantly reduces respiratory rate and dyspnea.",
                "relevance": 3
            },
            {
                "doc_id": "CPN40_5",
                "text": "Retrospective analyses suggest a moderate advantage for high-flow nasal cannula in avoiding intubation in certain patient subgroups.",
                "relevance": 3
            },
            {
                "doc_id": "CPN40_6",
                "text": "Current critical care guidelines increasingly recommend high-flow nasal cannula as a first-line option for acute hypoxemic respiratory failure, preventing escalation to invasive ventilation.",
                "relevance": 4
            },
            {
                "doc_id": "CPN40_7",
                "text": "Large-scale randomized controlled trials and meta-analyses conclusively demonstrate high-flow nasal cannula's superior efficacy over conventional oxygen therapy in reducing intubation rates and improving clinical outcomes in acute hypoxemic respiratory failure.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN41",
        "query_type": "comparative_NOT",
        "query_text": "Are beta-lactam antibiotics better than macrolides for community-acquired pneumonia in adults (CAP)?",
        "documents": [
            {
                "doc_id": "CPN41_1",
                "text": "Just hitting pneumonia with beta-lactams might not be enough; you sometimes need macrolides for the 'atypical' stuff.",
                "relevance": 1
            },
            {
                "doc_id": "CPN41_2",
                "text": "For community-acquired pneumonia, beta-lactam monotherapy does not consistently provide broad-spectrum coverage for atypical pathogens, which macrolides address.",
                "relevance": 1
            },
            {
                "doc_id": "CPN41_3",
                "text": "While beta-lactams effectively cover typical bacterial causes, some CAP cases involve organisms better covered by macrolides.",
                "relevance": 2
            },
            {
                "doc_id": "CPN41_4",
                "text": "A moderate number of studies indicate that combination therapy (beta-lactam plus macrolide) often leads to better clinical outcomes in severe CAP.",
                "relevance": 3
            },
            {
                "doc_id": "CPN41_5",
                "text": "Retrospective analyses suggest a moderate advantage for macrolides or combination therapy in reducing mortality in specific CAP patient subgroups.",
                "relevance": 3
            },
            {
                "doc_id": "CPN41_6",
                "text": "International guidelines often recommend combination therapy with a beta-lactam and a macrolide for hospitalized CAP patients, particularly those with more severe disease.",
                "relevance": 4
            },
            {
                "doc_id": "CPN41_7",
                "text": "Comprehensive meta-analyses demonstrate that while beta-lactams are foundational, the addition of macrolides is crucial for optimal coverage and improved outcomes in many adult CAP cases, meaning beta-lactam monotherapy is not universally better.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN42",
        "query_type": "comparative_NOT",
        "query_text": "Are DMARDs better than NSAIDs for delaying disease progression in rheumatoid arthritis?",
        "documents": [
            {
                "doc_id": "CPN42_1",
                "text": "NSAIDs just help with pain; they don't actually stop your joints from getting wrecked in RA, like DMARDs can.",
                "relevance": 1
            },
            {
                "doc_id": "CPN42_2",
                "text": "NSAIDs offer symptomatic relief but do not alter the course of rheumatoid arthritis or prevent joint destruction, unlike DMARDs.",
                "relevance": 1
            },
            {
                "doc_id": "CPN42_3",
                "text": "While NSAIDs reduce inflammation and pain, their effects are palliative and do not address the underlying autoimmune pathology.",
                "relevance": 2
            },
            {
                "doc_id": "CPN42_4",
                "text": "A moderate number of studies indicate DMARDs significantly slow radiographic progression and preserve joint function in RA.",
                "relevance": 3
            },
            {
                "doc_id": "CPN42_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for DMARDs in terms of long-term disease modification and preventing disability.",
                "relevance": 3
            },
            {
                "doc_id": "CPN42_6",
                "text": "Rheumatology guidelines unequivocally recommend DMARDs as the cornerstone of therapy for rheumatoid arthritis to prevent disease progression.",
                "relevance": 4
            },
            {
                "doc_id": "CPN42_7",
                "text": "Extensive randomized controlled trials and long-term observational studies conclusively demonstrate DMARDs are vastly superior to NSAIDs for delaying disease progression and preventing irreversible joint damage in rheumatoid arthritis.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN43",
        "query_type": "comparative_NOT",
        "query_text": "Is intravenous immunoglobulin (IVIG) better than plasma exchange (PLEX) for acute Guillain-Barr Syndrome (GBS)?",
        "documents": [
            {
                "doc_id": "CPN43_1",
                "text": "Both treatments for GBS are pretty good, so it's not like one is miles ahead of the other, but IVIG is often easier to use.",
                "relevance": 1
            },
            {
                "doc_id": "CPN43_2",
                "text": "Systematic reviews have not consistently demonstrated IVIG's superior efficacy over plasma exchange in improving functional outcomes in acute GBS.",
                "relevance": 1
            },
            {
                "doc_id": "CPN43_3",
                "text": "Early trials showed both treatments lead to similar rates of functional recovery, though their side effect profiles differ.",
                "relevance": 2
            },
            {
                "doc_id": "CPN43_4",
                "text": "A moderate number of studies indicate IVIG is generally associated with fewer severe systemic adverse events, making it moderately safer or more convenient.",
                "relevance": 3
            },
            {
                "doc_id": "CPN43_5",
                "text": "Retrospective analyses suggest a moderate comparability in neurological recovery, with IVIG offering benefits in terms of ease of administration.",
                "relevance": 3
            },
            {
                "doc_id": "CPN43_6",
                "text": "Current neurological guidelines often consider IVIG and PLEX equally effective for GBS, with choice depending on patient factors and accessibility.",
                "relevance": 4
            },
            {
                "doc_id": "CPN43_7",
                "text": "Comprehensive meta-analyses of randomized controlled trials consistently show IVIG and plasma exchange have comparable efficacy in acute GBS, though IVIG's less invasive nature often makes it the preferred option, meaning it is not clinically 'better' in terms of outcome.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN44",
        "query_type": "comparative_NOT",
        "query_text": "Are inhaled corticosteroids (ICS) better than oral leukotriene receptor antagonists (LTRAs) for long-term asthma control in children?",
        "documents": [
            {
                "doc_id": "CPN44_1",
                "text": "Just using LTRAs for daily asthma in kids? That's probably not cutting it if their asthma is more than super mild.",
                "relevance": 1
            },
            {
                "doc_id": "CPN44_2",
                "text": "Oral leukotriene receptor antagonists do not consistently provide the same level of long-term asthma control as inhaled corticosteroids in children, especially for moderate-to-severe disease.",
                "relevance": 1
            },
            {
                "doc_id": "CPN44_3",
                "text": "While LTRAs are useful, particularly for exercise-induced asthma or allergic rhinitis, their anti-inflammatory effect on the airways is generally less potent than ICS.",
                "relevance": 2
            },
            {
                "doc_id": "CPN44_4",
                "text": "A moderate number of studies indicate ICS significantly reduce exacerbation rates and improve lung function in pediatric asthma.",
                "relevance": 3
            },
            {
                "doc_id": "CPN44_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for ICS in achieving sustained symptom control and preventing disease progression.",
                "relevance": 3
            },
            {
                "doc_id": "CPN44_6",
                "text": "International asthma guidelines unequivocally recommend inhaled corticosteroids as the first-line controller therapy for persistent asthma in children.",
                "relevance": 4
            },
            {
                "doc_id": "CPN44_7",
                "text": "Extensive randomized controlled trials and meta-analyses conclusively demonstrate ICS's superior efficacy over oral LTRAs in achieving optimal long-term asthma control, reducing exacerbations, and improving lung function in children.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN45",
        "query_type": "comparative_NOT",
        "query_text": "Is transdermal fentanyl better than oral morphine for chronic severe non-cancer pain?",
        "documents": [
            {
                "doc_id": "CPN45_1",
                "text": "While fentanyl is strong, it's not always the go-to first choice for chronic pain, and oral morphine can be just as good for many.",
                "relevance": 1
            },
            {
                "doc_id": "CPN45_2",
                "text": "Transdermal fentanyl is not universally superior to oral morphine for managing chronic severe non-cancer pain; individual patient response and side effect profiles vary.",
                "relevance": 1
            },
            {
                "doc_id": "CPN45_3",
                "text": "Both opioids are potent, but fentanyl's slow onset and specific pharmacokinetic profile make it less suitable for rapid dose adjustments, unlike oral morphine.",
                "relevance": 2
            },
            {
                "doc_id": "CPN45_4",
                "text": "A moderate number of studies indicate comparable analgesic efficacy for both, with fentanyl offering convenience of less frequent dosing.",
                "relevance": 3
            },
            {
                "doc_id": "CPN45_5",
                "text": "Retrospective analyses suggest a moderate comparability in overall pain relief, but with different side effect profiles (e.g., less constipation with fentanyl for some).",
                "relevance": 3
            },
            {
                "doc_id": "CPN45_6",
                "text": "Clinical guidelines generally recommend a stepwise approach to opioid therapy, with oral opioids often preferred as first-line due to ease of titration and cost-effectiveness.",
                "relevance": 4
            },
            {
                "doc_id": "CPN45_7",
                "text": "Systematic reviews and comparative studies demonstrate that while transdermal fentanyl provides effective analgesia, it is not consistently superior to appropriately dosed oral morphine for chronic severe non-cancer pain, particularly concerning initial titration and patient-specific side effect management.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN46",
        "query_type": "comparative_NOT",
        "query_text": "Are loop diuretics better than thiazide diuretics for managing edema in heart failure?",
        "documents": [
            {
                "doc_id": "CPN46_1",
                "text": "Thiazides are okay for mild swelling, but for real heart failure edema, you need the big guns like loop diuretics.",
                "relevance": 1
            },
            {
                "doc_id": "CPN46_2",
                "text": "Thiazide diuretics are less potent than loop diuretics and lose efficacy in patients with significant renal impairment, common in heart failure.",
                "relevance": 1
            },
            {
                "doc_id": "CPN46_3",
                "text": "While thiazides effectively lower blood pressure, their diuretic capacity is often insufficient to resolve significant volume overload in advanced heart failure.",
                "relevance": 2
            },
            {
                "doc_id": "CPN46_4",
                "text": "A moderate number of studies indicate loop diuretics achieve greater diuresis and symptom relief in patients with acute and chronic decompensated heart failure.",
                "relevance": 3
            },
            {
                "doc_id": "CPN46_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for loop diuretics in managing fluid retention in moderate-to-severe heart failure.",
                "relevance": 3
            },
            {
                "doc_id": "CPN46_6",
                "text": "Cardiology guidelines consistently recommend loop diuretics as the primary class of diuretics for managing edema in heart failure due to their potent diuretic effect.",
                "relevance": 4
            },
            {
                "doc_id": "CPN46_7",
                "text": "Extensive clinical trials and meta-analyses conclusively demonstrate the superior efficacy of loop diuretics over thiazide diuretics for managing edema and improving symptoms in heart failure, especially in the context of reduced renal function.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN47",
        "query_type": "comparative_NOT",
        "query_text": "Are proton pump inhibitors (PPIs) better than antacids for immediate heartburn relief?",
        "documents": [
            {
                "doc_id": "CPN47_1",
                "text": "Nope, if you need immediate relief, a PPI is not going to cut it; reach for an antacid.",
                "relevance": 1
            },
            {
                "doc_id": "CPN47_2",
                "text": "Proton pump inhibitors have a delayed onset of action and are not suitable for immediate heartburn relief, unlike antacids.",
                "relevance": 1
            },
            {
                "doc_id": "CPN47_3",
                "text": "While PPIs are excellent for long-term acid suppression, their mechanism requires time to take effect, making them ineffective for acute symptom resolution.",
                "relevance": 2
            },
            {
                "doc_id": "CPN47_4",
                "text": "A moderate number of studies confirm antacids provide rapid neutralization of stomach acid, leading to quick heartburn relief.",
                "relevance": 3
            },
            {
                "doc_id": "CPN47_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for antacids in terms of speed of symptom alleviation.",
                "relevance": 3
            },
            {
                "doc_id": "CPN47_6",
                "text": "Pharmacology guidelines clearly state that antacids are indicated for immediate heartburn relief, while PPIs are for persistent or chronic acid-related conditions.",
                "relevance": 4
            },
            {
                "doc_id": "CPN47_7",
                "text": "Clinical pharmacology studies definitively demonstrate that antacids are vastly superior to proton pump inhibitors for providing immediate relief from heartburn symptoms due to their direct acid-neutralizing action.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN48",
        "query_type": "comparative_NOT",
        "query_text": "Is cognitive behavioral therapy (CBT) better than pharmacotherapy for relapse prevention in panic disorder?",
        "documents": [
            {
                "doc_id": "CPN48_1",
                "text": "Just taking pills for panic might help now, but for staying better long-term, therapy often works a treat.",
                "relevance": 1
            },
            {
                "doc_id": "CPN48_2",
                "text": "Pharmacotherapy alone is not consistently superior to CBT for long-term relapse prevention in panic disorder, and often carries discontinuation challenges.",
                "relevance": 1
            },
            {
                "doc_id": "CPN48_3",
                "text": "While medication offers symptom reduction, CBT provides coping skills and cognitive restructuring that contribute to more durable remission.",
                "relevance": 2
            },
            {
                "doc_id": "CPN48_4",
                "text": "A moderate number of studies indicate CBT provides sustained benefits in terms of relapse prevention, even after therapy concludes.",
                "relevance": 3
            },
            {
                "doc_id": "CPN48_5",
                "text": "Retrospective analyses suggest a moderate but consistent advantage for CBT in maintaining remission and preventing recurrence of panic attacks.",
                "relevance": 3
            },
            {
                "doc_id": "CPN48_6",
                "text": "Leading mental health guidelines often recommend CBT, either alone or in combination with pharmacotherapy, as a preferred strategy for long-term panic disorder management and relapse prevention.",
                "relevance": 4
            },
            {
                "doc_id": "CPN48_7",
                "text": "Comprehensive meta-analyses and long-term follow-up studies unequivocally demonstrate CBT's superior efficacy over pharmacotherapy alone for long-term relapse prevention and sustained remission in panic disorder.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN49",
        "query_type": "comparative_NOT",
        "query_text": "Are combination oral contraceptives better than progestin-only pills for acne treatment?",
        "documents": [
            {
                "doc_id": "CPN49_1",
                "text": "The mini-pill often does nothing for acne, and sometimes even makes it worse. You need estrogen for that.",
                "relevance": 1
            },
            {
                "doc_id": "CPN49_2",
                "text": "Progestin-only pills are generally not effective for treating acne and can sometimes exacerbate it due to their androgenic effects.",
                "relevance": 1
            },
            {
                "doc_id": "CPN49_3",
                "text": "While progestin-only pills are suitable for contraception, they lack the estrogen component necessary to suppress ovarian androgens linked to acne.",
                "relevance": 2
            },
            {
                "doc_id": "CPN49_4",
                "text": "A moderate body of evidence indicates combination oral contraceptives, particularly those with anti-androgenic progestins, significantly improve acne.",
                "relevance": 3
            },
            {
                "doc_id": "CPN49_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for combination oral contraceptives in reducing lesion counts and improving skin appearance.",
                "relevance": 3
            },
            {
                "doc_id": "CPN49_6",
                "text": "Dermatology and gynecology guidelines recommend specific formulations of combination oral contraceptives as an effective treatment option for hormonal acne.",
                "relevance": 4
            },
            {
                "doc_id": "CPN49_7",
                "text": "Large-scale clinical trials and systematic reviews conclusively demonstrate combination oral contraceptives are vastly superior to progestin-only pills for the effective treatment of acne by regulating hormonal influences.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN50",
        "query_type": "comparative_NOT",
        "query_text": "Are calcineurin inhibitors better than methotrexate for preventing graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation?",
        "documents": [
            {
                "doc_id": "CPN50_1",
                "text": "Honestly, just one drug like methotrexate for GVHD prevention isn't usually enough; you typically need calcineurin inhibitors too.",
                "relevance": 1
            },
            {
                "doc_id": "CPN50_2",
                "text": "Methotrexate monotherapy is not consistently effective for preventing severe GVHD after hematopoietic stem cell transplantation, unlike calcineurin inhibitor-based regimens.",
                "relevance": 1
            },
            {
                "doc_id": "CPN50_3",
                "text": "While methotrexate has a role, its mechanism of action alone often provides insufficient immunosuppression to prevent GVHD adequately.",
                "relevance": 2
            },
            {
                "doc_id": "CPN50_4",
                "text": "A moderate number of studies indicate calcineurin inhibitors (e.g., cyclosporine, tacrolimus) are highly effective in suppressing T-cell activation, a key driver of GVHD.",
                "relevance": 3
            },
            {
                "doc_id": "CPN50_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for calcineurin inhibitors, typically in combination with other agents, in reducing GVHD incidence.",
                "relevance": 3
            },
            {
                "doc_id": "CPN50_6",
                "text": "Standard clinical practice and guidelines for hematopoietic stem cell transplantation universally include a calcineurin inhibitor as the backbone of GVHD prophylaxis.",
                "relevance": 4
            },
            {
                "doc_id": "CPN50_7",
                "text": "Large-scale randomized controlled trials and meta-analyses conclusively demonstrate that calcineurin inhibitors, typically in combination with short-course methotrexate or other agents, are vastly superior to methotrexate alone for preventing severe graft-versus-host disease after hematopoietic stem cell transplantation.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN51",
        "query_type": "comparative_NOT",
        "query_text": "Are SSRIs better than benzodiazepines for long-term management of Post-Traumatic Stress Disorder (PTSD)?",
        "documents": [
            {
                "doc_id": "CPN51_1",
                "text": "Benzos are a quick fix for anxiety, but they don't solve the root of PTSD, and you can get hooked.",
                "relevance": 1
            },
            {
                "doc_id": "CPN51_2",
                "text": "Benzodiazepines are not recommended for long-term management of PTSD due to risks of dependence, tolerance, and lack of efficacy for core PTSD symptoms.",
                "relevance": 1
            },
            {
                "doc_id": "CPN51_3",
                "text": "While benzodiazepines can reduce acute anxiety in PTSD, they do not address the intrusive thoughts, nightmares, or hyperarousal components effectively in the long run.",
                "relevance": 2
            },
            {
                "doc_id": "CPN51_4",
                "text": "A moderate number of studies indicate SSRIs significantly reduce overall PTSD symptom severity and improve functional outcomes.",
                "relevance": 3
            },
            {
                "doc_id": "CPN51_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for SSRIs in promoting sustained remission and preventing relapse in PTSD.",
                "relevance": 3
            },
            {
                "doc_id": "CPN51_6",
                "text": "Clinical guidelines consistently recommend SSRIs (sertraline, paroxetine) as first-line pharmacological treatment for PTSD due to their efficacy and safety profile for long-term use.",
                "relevance": 4
            },
            {
                "doc_id": "CPN51_7",
                "text": "Extensive randomized controlled trials and meta-analyses conclusively demonstrate SSRIs are vastly superior to benzodiazepines for long-term management and core symptom reduction in PTSD.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN52",
        "query_type": "comparative_NOT",
        "query_text": "Is naltrexone better than disulfiram for reducing alcohol cravings in Alcohol Use Disorder (AUD)?",
        "documents": [
            {
                "doc_id": "CPN52_1",
                "text": "Disulfiram just makes you sick if you drink; naltrexone actually helps with the desire to drink, which is a lot more useful.",
                "relevance": 1
            },
            {
                "doc_id": "CPN52_2",
                "text": "Disulfiram primarily acts as an aversion therapy by causing unpleasant reactions to alcohol, but it does not directly reduce alcohol cravings like naltrexone.",
                "relevance": 1
            },
            {
                "doc_id": "CPN52_3",
                "text": "While disulfiram can deter drinking, its effectiveness relies on patient adherence and does not address the underlying neurobiological cravings.",
                "relevance": 2
            },
            {
                "doc_id": "CPN52_4",
                "text": "A moderate number of studies indicate naltrexone significantly reduces alcohol cravings and heavy drinking days in AUD patients.",
                "relevance": 3
            },
            {
                "doc_id": "CPN52_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for naltrexone in terms of improving abstinence rates and reducing relapse.",
                "relevance": 3
            },
            {
                "doc_id": "CPN52_6",
                "text": "Clinical guidelines recommend naltrexone as a first-line pharmacological agent for AUD, specifically for its craving-reducing properties.",
                "relevance": 4
            },
            {
                "doc_id": "CPN52_7",
                "text": "Comprehensive meta-analyses and randomized controlled trials unequivocally demonstrate naltrexone's superior efficacy over disulfiram in directly reducing alcohol cravings and promoting sustained recovery in Alcohol Use Disorder.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN53",
        "query_type": "comparative_NOT",
        "query_text": "Is buprenorphine better than naltrexone for opioid use disorder (OUD) during the initial phases of treatment?",
        "documents": [
            {
                "doc_id": "CPN53_1",
                "text": "Naltrexone can be hard to start because of withdrawal; buprenorphine is easier and safer early on for opioid addiction.",
                "relevance": 1
            },
            {
                "doc_id": "CPN53_2",
                "text": "Naltrexone requires complete opioid detoxification before initiation, which can be challenging and carries a risk of precipitating withdrawal if not done carefully.",
                "relevance": 1
            },
            {
                "doc_id": "CPN53_3",
                "text": "While naltrexone is effective for relapse prevention, its requirement for opioid-free status makes initial engagement and adherence more difficult for many patients.",
                "relevance": 2
            },
            {
                "doc_id": "CPN53_4",
                "text": "A moderate number of studies indicate buprenorphine-naloxone facilitates smoother induction and retention in treatment, especially in outpatient settings.",
                "relevance": 3
            },
            {
                "doc_id": "CPN53_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for buprenorphine in terms of ease of initiation and patient engagement in the early stages of OUD treatment.",
                "relevance": 3
            },
            {
                "doc_id": "CPN53_6",
                "text": "Clinical guidelines often recommend buprenorphine-naloxone as a preferred first-line medication for OUD due to its ability to be initiated in an outpatient setting and mitigate withdrawal.",
                "relevance": 4
            },
            {
                "doc_id": "CPN53_7",
                "text": "Randomized controlled trials and meta-analyses conclusively demonstrate buprenorphine's superior safety and feasibility over naltrexone for initial treatment and induction in opioid use disorder, largely due to its ability to suppress withdrawal symptoms.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN54",
        "query_type": "comparative_NOT",
        "query_text": "Are stimulant medications better than non-stimulant medications for rapidly improving ADHD symptoms in adults?",
        "documents": [
            {
                "doc_id": "CPN54_1",
                "text": "If you need ADHD symptoms to get better fast, stimulants are the way to go; non-stimulants take ages to kick in.",
                "relevance": 1
            },
            {
                "doc_id": "CPN54_2",
                "text": "Non-stimulant medications for ADHD have a delayed onset of action, often taking several weeks to show full therapeutic effects, unlike stimulants.",
                "relevance": 1
            },
            {
                "doc_id": "CPN54_3",
                "text": "While non-stimulants are valuable for long-term management or when stimulants are contraindicated, they do not provide the rapid symptomatic relief seen with stimulants.",
                "relevance": 2
            },
            {
                "doc_id": "CPN54_4",
                "text": "A moderate number of studies indicate stimulant medications produce significant and immediate improvements in attention, hyperactivity, and impulsivity.",
                "relevance": 3
            },
            {
                "doc_id": "CPN54_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for stimulants in achieving rapid symptom reduction and functional improvement.",
                "relevance": 3
            },
            {
                "doc_id": "CPN54_6",
                "text": "Clinical guidelines consistently recommend stimulants as first-line pharmacotherapy for ADHD in adults due to their rapid onset of action and strong efficacy.",
                "relevance": 4
            },
            {
                "doc_id": "CPN54_7",
                "text": "Large-scale randomized controlled trials and meta-analyses unequivocally demonstrate the superior rapid onset of action and acute efficacy of stimulant medications over non-stimulants for improving ADHD symptoms in adults.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN55",
        "query_type": "comparative_NOT",
        "query_text": "Are atypical antipsychotics better than lithium for acute mania in bipolar disorder, regarding tolerability?",
        "documents": [
            {
                "doc_id": "CPN55_1",
                "text": "Lithium works for mania, but the side effects and blood tests can be a pain; atypical antipsychotics are often easier to deal with.",
                "relevance": 1
            },
            {
                "doc_id": "CPN55_2",
                "text": "Lithium often requires careful therapeutic drug monitoring and can be associated with a narrower therapeutic window and more frequent side effects like tremor and kidney issues.",
                "relevance": 1
            },
            {
                "doc_id": "CPN55_3",
                "text": "While highly effective, lithium's side effect profile and need for monitoring can lead to lower adherence rates compared to some atypical antipsychotics.",
                "relevance": 2
            },
            {
                "doc_id": "CPN55_4",
                "text": "A moderate number of studies indicate atypical antipsychotics have a generally favorable acute tolerability profile, often with fewer gastrointestinal or neurological side effects.",
                "relevance": 3
            },
            {
                "doc_id": "CPN55_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for atypical antipsychotics in terms of patient-reported tolerability and ease of initiation.",
                "relevance": 3
            },
            {
                "doc_id": "CPN55_6",
                "text": "Clinical guidelines often recommend atypical antipsychotics, alongside lithium or valproate, as first-line options for acute mania due to their rapid onset and generally acceptable tolerability.",
                "relevance": 4
            },
            {
                "doc_id": "CPN55_7",
                "text": "Comprehensive meta-analyses and randomized controlled trials show that while both are effective, atypical antipsychotics generally have a superior acute tolerability profile compared to lithium for treating acute mania in bipolar disorder.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN56",
        "query_type": "comparative_NOT",
        "query_text": "Is Cognitive Behavioral Therapy for Insomnia (CBT-I) better than zolpidem for long-term insomnia management?",
        "documents": [
            {
                "doc_id": "CPN56_1",
                "text": "Sleeping pills are just a band-aid; for real, lasting sleep improvement, you need something like CBT-I.",
                "relevance": 1
            },
            {
                "doc_id": "CPN56_2",
                "text": "Zolpidem and other hypnotics are associated with risks of dependence, tolerance, and rebound insomnia upon discontinuation, making them less suitable for long-term use.",
                "relevance": 1
            },
            {
                "doc_id": "CPN56_3",
                "text": "While zolpidem provides quick sleep onset, its efficacy often wanes over time, and it does not address the underlying behavioral or cognitive factors contributing to insomnia.",
                "relevance": 2
            },
            {
                "doc_id": "CPN56_4",
                "text": "A moderate number of studies indicate CBT-I provides sustained improvements in sleep onset, duration, and quality, enduring beyond the active treatment phase.",
                "relevance": 3
            },
            {
                "doc_id": "CPN56_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for CBT-I in terms of durable remission and prevention of relapse into chronic insomnia.",
                "relevance": 3
            },
            {
                "doc_id": "CPN56_6",
                "text": "Medical guidelines consistently recommend CBT-I as the first-line and most effective long-term treatment for chronic insomnia, due to its durable effects and lack of side effects seen with medications.",
                "relevance": 4
            },
            {
                "doc_id": "CPN56_7",
                "text": "Extensive randomized controlled trials and long-term follow-up studies unequivocally demonstrate CBT-I's superior efficacy over zolpidem for sustained improvement and relapse prevention in chronic insomnia.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN57",
        "query_type": "comparative_NOT",
        "query_text": "Are non-ergot dopamine agonists better than levodopa for long-term management of Restless Legs Syndrome (RLS), regarding augmentation?",
        "documents": [
            {
                "doc_id": "CPN57_1",
                "text": "Levodopa works for RLS, but it often stops working well over time, unlike other meds that last longer.",
                "relevance": 1
            },
            {
                "doc_id": "CPN57_2",
                "text": "Levodopa therapy for RLS is significantly associated with the risk of augmentation (worsening of symptoms or earlier onset) with long-term use.",
                "relevance": 1
            },
            {
                "doc_id": "CPN57_3",
                "text": "While levodopa provides rapid symptom relief, its short half-life and pulsatile stimulation of dopamine receptors contribute to higher rates of augmentation.",
                "relevance": 2
            },
            {
                "doc_id": "CPN57_4",
                "text": "A moderate number of studies indicate non-ergot dopamine agonists (e.g., pramipexole, ropinirole) have a lower risk of augmentation compared to levodopa.",
                "relevance": 3
            },
            {
                "doc_id": "CPN57_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for non-ergot dopamine agonists in terms of sustained efficacy and reduced risk of symptom worsening.",
                "relevance": 3
            },
            {
                "doc_id": "CPN57_6",
                "text": "Neurology guidelines recommend non-ergot dopamine agonists as first-line pharmacotherapy for chronic RLS due to their sustained efficacy and lower risk of augmentation.",
                "relevance": 4
            },
            {
                "doc_id": "CPN57_7",
                "text": "Comprehensive meta-analyses and long-term observational studies conclusively demonstrate non-ergot dopamine agonists are superior to levodopa for long-term RLS management, primarily due to a significantly lower risk of augmentation.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN58",
        "query_type": "comparative_NOT",
        "query_text": "Are CGRP monoclonal antibodies better than beta-blockers for migraine prophylaxis, regarding side effects?",
        "documents": [
            {
                "doc_id": "CPN58_1",
                "text": "Beta-blockers can make you tired and lower your blood pressure, but the new migraine drugs usually don't have those issues.",
                "relevance": 1
            },
            {
                "doc_id": "CPN58_2",
                "text": "Beta-blockers commonly cause side effects such as fatigue, bradycardia, and hypotension, which can limit adherence in migraine prophylaxis.",
                "relevance": 1
            },
            {
                "doc_id": "CPN58_3",
                "text": "While effective, beta-blockers' broad systemic effects often lead to a less favorable tolerability profile compared to more targeted therapies.",
                "relevance": 2
            },
            {
                "doc_id": "CPN58_4",
                "text": "A moderate number of studies indicate CGRP monoclonal antibodies have a generally well-tolerated safety profile with fewer systemic side effects.",
                "relevance": 3
            },
            {
                "doc_id": "CPN58_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for CGRP monoclonal antibodies in terms of patient-reported tolerability and continuation rates.",
                "relevance": 3
            },
            {
                "doc_id": "CPN58_6",
                "text": "Recent guidelines for migraine prophylaxis highlight CGRP monoclonal antibodies for their targeted mechanism and generally favorable side effect profile.",
                "relevance": 4
            },
            {
                "doc_id": "CPN58_7",
                "text": "Randomized controlled trials and meta-analyses conclusively demonstrate CGRP monoclonal antibodies have a superior side effect profile compared to beta-blockers for migraine prophylaxis, leading to better tolerability and adherence.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN59",
        "query_type": "comparative_NOT",
        "query_text": "Is pregabalin better than tricyclic antidepressants for reducing pain in fibromyalgia, regarding tolerability?",
        "documents": [
            {
                "doc_id": "CPN59_1",
                "text": "TCAs can help with fibromyalgia pain, but their side effects like dry mouth and drowsiness are often worse than what you get with pregabalin.",
                "relevance": 1
            },
            {
                "doc_id": "CPN59_2",
                "text": "Tricyclic antidepressants (TCAs) are associated with anticholinergic side effects (e.g., dry mouth, constipation, sedation) that can limit their tolerability in fibromyalgia patients.",
                "relevance": 1
            },
            {
                "doc_id": "CPN59_3",
                "text": "While TCAs are effective for some, their broader side effect profile often leads to lower patient acceptance and adherence for chronic use.",
                "relevance": 2
            },
            {
                "doc_id": "CPN59_4",
                "text": "A moderate number of studies indicate pregabalin provides significant pain reduction with a generally manageable side effect profile.",
                "relevance": 3
            },
            {
                "doc_id": "CPN59_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for pregabalin in terms of overall patient tolerability and better long-term adherence.",
                "relevance": 3
            },
            {
                "doc_id": "CPN59_6",
                "text": "Clinical guidelines often list pregabalin as a first-line agent for fibromyalgia, partly due to its relatively favorable tolerability compared to older antidepressants.",
                "relevance": 4
            },
            {
                "doc_id": "CPN59_7",
                "text": "Large-scale randomized controlled trials and meta-analyses conclusively demonstrate pregabalin's superior tolerability profile over tricyclic antidepressants for reducing pain in fibromyalgia, leading to better patient adherence and sustained benefit.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN60",
        "query_type": "comparative_NOT",
        "query_text": "Are linaclotide/lubiprostone better than fiber supplements for treating chronic idiopathic constipation (CIC)?",
        "documents": [
            {
                "doc_id": "CPN60_1",
                "text": "Fiber is a good start, but for serious chronic constipation, you often need stronger medications like linaclotide.",
                "relevance": 1
            },
            {
                "doc_id": "CPN60_2",
                "text": "Fiber supplements are often insufficient for achieving satisfactory bowel movements in patients with moderate-to-severe chronic idiopathic constipation.",
                "relevance": 1
            },
            {
                "doc_id": "CPN60_3",
                "text": "While dietary fiber can help mild constipation, it often does not fully address the underlying pathophysiology or provide adequate relief in persistent CIC.",
                "relevance": 2
            },
            {
                "doc_id": "CPN60_4",
                "text": "A moderate number of studies indicate linaclotide and lubiprostone significantly increase bowel movement frequency and improve stool consistency.",
                "relevance": 3
            },
            {
                "doc_id": "CPN60_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for these agents in achieving more complete and regular bowel habits.",
                "relevance": 3
            },
            {
                "doc_id": "CPN60_6",
                "text": "Gastroenterology guidelines recommend linaclotide and lubiprostone for patients with CIC who do not respond adequately to lifestyle modifications and over-the-counter laxatives.",
                "relevance": 4
            },
            {
                "doc_id": "CPN60_7",
                "text": "Large-scale randomized controlled trials and meta-analyses conclusively demonstrate linaclotide and lubiprostone's superior efficacy over fiber supplements for treating chronic idiopathic constipation, providing more consistent and complete symptom relief.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN61",
        "query_type": "comparative_NOT",
        "query_text": "Are antimuscarinics better than beta-3 agonists for reducing dry mouth side effects in overactive bladder (OAB) treatment?",
        "documents": [
            {
                "doc_id": "CPN61_1",
                "text": "Antimuscarinics often give you a really dry mouth; the newer drugs don't do that as much.",
                "relevance": 1
            },
            {
                "doc_id": "CPN61_2",
                "text": "Antimuscarinic agents commonly cause dry mouth due to their systemic anticholinergic effects, which can significantly impact patient quality of life.",
                "relevance": 1
            },
            {
                "doc_id": "CPN61_3",
                "text": "While effective for OAB symptoms, the broad receptor activity of antimuscarinics leads to a higher incidence of dry mouth compared to more selective agents.",
                "relevance": 2
            },
            {
                "doc_id": "CPN61_4",
                "text": "A moderate number of studies indicate beta-3 agonists (e.g., mirabegron, vibegron) have a significantly lower incidence of dry mouth due to their bladder-specific mechanism.",
                "relevance": 3
            },
            {
                "doc_id": "CPN61_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for beta-3 agonists in terms of patient-reported tolerability concerning xerostomia.",
                "relevance": 3
            },
            {
                "doc_id": "CPN61_6",
                "text": "Urology guidelines recommend beta-3 agonists as an alternative or first-line option for OAB, especially in patients where dry mouth with antimuscarinics is a concern.",
                "relevance": 4
            },
            {
                "doc_id": "CPN61_7",
                "text": "Randomized controlled trials and meta-analyses conclusively demonstrate beta-3 agonists are superior to antimuscarinics for overactive bladder treatment when considering the reduction of dry mouth side effects, leading to better patient adherence.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN62",
        "query_type": "comparative_NOT",
        "query_text": "Are 5-alpha reductase inhibitors better than alpha-blockers for reducing prostate size in Benign Prostatic Hyperplasia (BPH)?",
        "documents": [
            {
                "doc_id": "CPN62_1",
                "text": "Alpha-blockers help with peeing right away, but they don't actually shrink the prostate like the other meds do.",
                "relevance": 1
            },
            {
                "doc_id": "CPN62_2",
                "text": "Alpha-blockers relax smooth muscle to improve urine flow but do not reduce prostate volume, while 5-alpha reductase inhibitors actively shrink the prostate gland.",
                "relevance": 1
            },
            {
                "doc_id": "CPN62_3",
                "text": "While alpha-blockers provide rapid symptomatic relief, their mechanism does not address the underlying prostatic growth, which 5-alpha reductase inhibitors do.",
                "relevance": 2
            },
            {
                "doc_id": "CPN62_4",
                "text": "A moderate number of studies indicate 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) achieve significant and sustained reductions in prostate volume.",
                "relevance": 3
            },
            {
                "doc_id": "CPN62_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for 5-alpha reductase inhibitors in terms of preventing BPH progression and reducing surgical risk in the long term.",
                "relevance": 3
            },
            {
                "doc_id": "CPN62_6",
                "text": "Urology guidelines recommend 5-alpha reductase inhibitors for BPH patients with larger prostates to reduce gland size and prevent disease progression.",
                "relevance": 4
            },
            {
                "doc_id": "CPN62_7",
                "text": "Large-scale randomized controlled trials and meta-analyses conclusively demonstrate that 5-alpha reductase inhibitors are vastly superior to alpha-blockers for reducing prostate size and slowing BPH progression.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN63",
        "query_type": "comparative_NOT",
        "query_text": "Are PDE5 inhibitors better than vacuum erection devices (VEDs) for first-line treatment of erectile dysfunction (ED)?",
        "documents": [
            {
                "doc_id": "CPN63_1",
                "text": "For ED, taking a pill is usually way easier and more preferred than messing around with a pump.",
                "relevance": 1
            },
            {
                "doc_id": "CPN63_2",
                "text": "Vacuum erection devices are effective but are often less preferred by patients due to their cumbersome nature, lack of spontaneity, and potential side effects.",
                "relevance": 1
            },
            {
                "doc_id": "CPN63_3",
                "text": "While VEDs provide a mechanical solution, they don't offer the physiological convenience or discreetness of oral medications.",
                "relevance": 2
            },
            {
                "doc_id": "CPN63_4",
                "text": "A moderate number of studies indicate PDE5 inhibitors are highly effective and generally well-tolerated, providing a convenient on-demand treatment option.",
                "relevance": 3
            },
            {
                "doc_id": "CPN63_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for PDE5 inhibitors in terms of patient satisfaction and ease of use as a first-line treatment.",
                "relevance": 3
            },
            {
                "doc_id": "CPN63_6",
                "text": "Urology guidelines consistently recommend PDE5 inhibitors as the first-line pharmacological treatment for ED due to their efficacy, safety, and patient preference.",
                "relevance": 4
            },
            {
                "doc_id": "CPN63_7",
                "text": "Extensive randomized controlled trials and meta-analyses conclusively demonstrate PDE5 inhibitors are vastly superior to vacuum erection devices as a first-line treatment for erectile dysfunction, primarily due to higher patient satisfaction and ease of use.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN64",
        "query_type": "comparative_NOT",
        "query_text": "Are SSRIs better than topical anesthetics for long-term management of premature ejaculation (PE)?",
        "documents": [
            {
                "doc_id": "CPN64_1",
                "text": "Topical creams help in the moment, but they don't fix the core issue of PE, and SSRIs can give a more lasting effect.",
                "relevance": 1
            },
            {
                "doc_id": "CPN64_2",
                "text": "Topical anesthetics primarily desensitize the penis for temporary relief but do not address the neurobiological mechanisms underlying premature ejaculation or provide long-term control.",
                "relevance": 1
            },
            {
                "doc_id": "CPN64_3",
                "text": "While effective for situational use, reliance on topical agents can detract from spontaneity and may not be suitable for consistent long-term management.",
                "relevance": 2
            },
            {
                "doc_id": "CPN64_4",
                "text": "A moderate number of studies indicate SSRIs significantly prolong ejaculation latency time and improve ejaculatory control with continuous use.",
                "relevance": 3
            },
            {
                "doc_id": "CPN64_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for SSRIs in terms of sustained improvement in ejaculatory control and overall sexual satisfaction.",
                "relevance": 3
            },
            {
                "doc_id": "CPN64_6",
                "text": "Urology guidelines recommend daily SSRI therapy as a primary pharmacological option for chronic premature ejaculation due to its consistent efficacy.",
                "relevance": 4
            },
            {
                "doc_id": "CPN64_7",
                "text": "Extensive randomized controlled trials and meta-analyses conclusively demonstrate SSRIs are vastly superior to topical anesthetics for long-term management and sustained improvement of ejaculatory control in premature ejaculation.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN65",
        "query_type": "comparative_NOT",
        "query_text": "Is hormone therapy (estrogen) better than gabapentin for reducing the frequency of menopausal hot flashes?",
        "documents": [
            {
                "doc_id": "CPN65_1",
                "text": "Hormone therapy is usually the best bet for hot flashes, way more effective than gabapentin, though gabapentin is an option if you can't take hormones.",
                "relevance": 1
            },
            {
                "doc_id": "CPN65_2",
                "text": "While gabapentin can reduce hot flash frequency, its efficacy is generally less robust than that of estrogen-based hormone therapy.",
                "relevance": 1
            },
            {
                "doc_id": "CPN65_3",
                "text": "Gabapentin offers a non-hormonal option, but its symptom reduction is often moderate and may not be as comprehensive as estrogen's effects on vasomotor symptoms.",
                "relevance": 2
            },
            {
                "doc_id": "CPN65_4",
                "text": "A moderate number of studies indicate hormone therapy provides significant and rapid reduction in the frequency and severity of hot flashes.",
                "relevance": 3
            },
            {
                "doc_id": "CPN65_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for hormone therapy in terms of overall symptom control and improved quality of life.",
                "relevance": 3
            },
            {
                "doc_id": "CPN65_6",
                "text": "Menopause societies and guidelines consistently state that hormone therapy is the most effective treatment for bothersome vasomotor symptoms like hot flashes.",
                "relevance": 4
            },
            {
                "doc_id": "CPN65_7",
                "text": "Extensive randomized controlled trials and meta-analyses conclusively demonstrate that hormone therapy (estrogen) is vastly superior to gabapentin for reducing the frequency and severity of menopausal hot flashes.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN66",
        "query_type": "comparative_NOT",
        "query_text": "Are 5-HT3 receptor antagonists better than dopamine receptor antagonists for preventing acute chemotherapy-induced nausea and vomiting (CINV)?",
        "documents": [
            {
                "doc_id": "CPN66_1",
                "text": "Older drugs for chemo nausea aren't nearly as good as the newer ones; they often leave patients still feeling sick.",
                "relevance": 1
            },
            {
                "doc_id": "CPN66_2",
                "text": "Dopamine receptor antagonists often provide less complete control over acute CINV and have a higher incidence of extrapyramidal side effects compared to 5-HT3 receptor antagonists.",
                "relevance": 1
            },
            {
                "doc_id": "CPN66_3",
                "text": "While dopamine receptor antagonists have some antiemetic properties, they are generally less potent and have a broader side effect profile than 5-HT3 receptor antagonists for highly emetogenic chemotherapy.",
                "relevance": 2
            },
            {
                "doc_id": "CPN66_4",
                "text": "A moderate number of studies indicate 5-HT3 receptor antagonists significantly reduce the incidence and severity of acute CINV.",
                "relevance": 3
            },
            {
                "doc_id": "CPN66_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for 5-HT3 receptor antagonists in achieving higher rates of complete response (no nausea/vomiting).",
                "relevance": 3
            },
            {
                "doc_id": "CPN66_6",
                "text": "Oncology guidelines consistently recommend 5-HT3 receptor antagonists as cornerstone agents for preventing acute CINV, especially with highly emetogenic chemotherapy.",
                "relevance": 4
            },
            {
                "doc_id": "CPN66_7",
                "text": "Large-scale randomized controlled trials and meta-analyses conclusively demonstrate 5-HT3 receptor antagonists are vastly superior to dopamine receptor antagonists for preventing acute chemotherapy-induced nausea and vomiting, offering higher efficacy and a more favorable side effect profile.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN67",
        "query_type": "comparative_NOT",
        "query_text": "Are thionamides better than radioactive iodine for achieving stable euthyroidism in Graves' disease with ophthalmopathy?",
        "documents": [
            {
                "doc_id": "CPN67_1",
                "text": "Radioactive iodine can actually make your eyes worse if you have Graves' eye disease, so it's not always the best choice.",
                "relevance": 1
            },
            {
                "doc_id": "CPN67_2",
                "text": "Radioactive iodine therapy can exacerbate or induce Graves' ophthalmopathy, making thionamides a preferred initial treatment in patients with active eye disease.",
                "relevance": 1
            },
            {
                "doc_id": "CPN67_3",
                "text": "While radioactive iodine is effective for hyperthyroidism, its potential to worsen eye symptoms means it's not always the optimal choice for those with existing ophthalmopathy.",
                "relevance": 2
            },
            {
                "doc_id": "CPN67_4",
                "text": "A moderate number of studies indicate thionamides effectively control hyperthyroidism and do not worsen or may even improve Graves' ophthalmopathy.",
                "relevance": 3
            },
            {
                "doc_id": "CPN67_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for thionamides in maintaining stable thyroid function without negatively impacting eye disease.",
                "relevance": 3
            },
            {
                "doc_id": "CPN67_6",
                "text": "Endocrinology guidelines recommend thionamides (e.g., methimazole) as the initial treatment of choice for Graves' disease patients with moderate-to-severe or active Graves' ophthalmopathy.",
                "relevance": 4
            },
            {
                "doc_id": "CPN67_7",
                "text": "Randomized controlled trials and systematic reviews conclusively demonstrate that thionamides are superior to radioactive iodine for managing Graves' disease in patients with ophthalmopathy, as they effectively control hyperthyroidism without worsening or potentially even improving eye symptoms.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN68",
        "query_type": "comparative_NOT",
        "query_text": "Are inhaled long-acting beta-agonists (LABAs) better than inhaled short-acting beta-agonists (SABAs) for daily maintenance therapy in persistent asthma?",
        "documents": [
            {
                "doc_id": "CPN68_1",
                "text": "Just using your rescue inhaler every day for asthma isn't going to control it; you need something that lasts longer.",
                "relevance": 1
            },
            {
                "doc_id": "CPN68_2",
                "text": "Short-acting beta-agonists are for rescue relief, not for daily maintenance therapy, and their regular use can even worsen asthma control.",
                "relevance": 1
            },
            {
                "doc_id": "CPN68_3",
                "text": "While SABAs provide quick symptom relief, their short duration of action and lack of anti-inflammatory effect make them unsuitable as monotherapy for persistent asthma.",
                "relevance": 2
            },
            {
                "doc_id": "CPN68_4",
                "text": "A moderate number of studies indicate LABAs (always in combination with ICS) significantly improve lung function and reduce exacerbations in persistent asthma.",
                "relevance": 3
            },
            {
                "doc_id": "CPN68_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for LABAs (as part of combination therapy) in terms of sustained symptom control and reduced need for rescue medication.",
                "relevance": 3
            },
            {
                "doc_id": "CPN68_6",
                "text": "Asthma guidelines unequivocally recommend inhaled corticosteroids (with or without LABAs) as controller therapy, explicitly stating that SABAs are not for daily maintenance.",
                "relevance": 4
            },
            {
                "doc_id": "CPN68_7",
                "text": "Large-scale randomized controlled trials and meta-analyses conclusively demonstrate that inhaled LABAs (when combined with ICS) are vastly superior to SABAs alone for daily maintenance therapy in persistent asthma, offering sustained bronchodilation and improved disease control.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN69",
        "query_type": "comparative_NOT",
        "query_text": "Is high-dose methotrexate with leucovorin rescue better than standard chemotherapy alone for preventing CNS relapse in high-risk acute lymphoblastic leukemia (ALL)?",
        "documents": [
            {
                "doc_id": "CPN69_1",
                "text": "Just regular chemo isn't good enough to keep ALL from coming back in the brain for high-risk kids; you need that high-dose methotrexate.",
                "relevance": 1
            },
            {
                "doc_id": "CPN69_2",
                "text": "Standard systemic chemotherapy alone does not adequately penetrate the central nervous system (CNS) to prevent CNS relapse in high-risk ALL.",
                "relevance": 1
            },
            {
                "doc_id": "CPN69_3",
                "text": "While standard chemotherapy controls systemic disease, the blood-brain barrier limits its effectiveness in preventing leukemic cells from hiding in the CNS.",
                "relevance": 2
            },
            {
                "doc_id": "CPN69_4",
                "text": "A moderate number of studies indicate high-dose methotrexate (HDMTX) with leucovorin rescue significantly reduces the incidence of CNS relapse.",
                "relevance": 3
            },
            {
                "doc_id": "CPN69_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for HDMTX in improving disease-free survival by targeting CNS disease effectively.",
                "relevance": 3
            },
            {
                "doc_id": "CPN69_6",
                "text": "Oncology protocols for high-risk ALL universally include high-dose methotrexate with leucovorin rescue as a crucial component of CNS directed therapy.",
                "relevance": 4
            },
            {
                "doc_id": "CPN69_7",
                "text": "Extensive clinical trials and meta-analyses conclusively demonstrate that high-dose methotrexate with leucovorin rescue is vastly superior to standard chemotherapy alone for preventing CNS relapse in high-risk acute lymphoblastic leukemia.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN70",
        "query_type": "comparative_NOT",
        "query_text": "Is insulin detemir better than NPH insulin for reducing nocturnal hypoglycemia in Type 1 Diabetes?",
        "documents": [
            {
                "doc_id": "CPN70_1",
                "text": "NPH insulin at night often makes blood sugar drop too low, but the newer long-acting insulins are much safer.",
                "relevance": 1
            },
            {
                "doc_id": "CPN70_2",
                "text": "NPH insulin has a pronounced peak of action that often coincides with sleep, leading to a higher risk of nocturnal hypoglycemia.",
                "relevance": 1
            },
            {
                "doc_id": "CPN70_3",
                "text": "While NPH is effective, its less predictable absorption profile contributes to greater variability in glucose levels and a higher incidence of nighttime lows.",
                "relevance": 2
            },
            {
                "doc_id": "CPN70_4",
                "text": "A moderate number of studies indicate insulin detemir (a basal insulin) provides a flatter, more prolonged glucose-lowering effect.",
                "relevance": 3
            },
            {
                "doc_id": "CPN70_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for insulin detemir in reducing the frequency of nocturnal hypoglycemic events.",
                "relevance": 3
            },
            {
                "doc_id": "CPN70_6",
                "text": "Diabetes guidelines often recommend newer basal insulins like detemir over NPH for Type 1 diabetes due to their reduced risk of hypoglycemia, particularly at night.",
                "relevance": 4
            },
            {
                "doc_id": "CPN70_7",
                "text": "Large-scale randomized controlled trials and meta-analyses conclusively demonstrate insulin detemir's superior efficacy over NPH insulin in reducing the incidence of nocturnal hypoglycemia in Type 1 Diabetes.",
                "relevance": 5
            }
        ]
    },
    {
        "query_id": "CPN71",
        "query_type": "comparative_NOT",
        "query_text": "Is adalimumab better than etanercept for inducing remission in severe ulcerative colitis?",
        "documents": [
            {
                "doc_id": "CPN71_1",
                "text": "Etanercept isn't really used for severe ulcerative colitis; adalimumab is the one that actually works for that.",
                "relevance": 1
            },
            {
                "doc_id": "CPN71_2",
                "text": "Etanercept is not effective for inducing remission in ulcerative colitis due to its different mechanism of action (it primarily targets TNF-alpha, but not the specific pathways relevant to UC).",
                "relevance": 1
            },
            {
                "doc_id": "CPN71_3",
                "text": "While etanercept is used for other inflammatory conditions, it has consistently failed to demonstrate efficacy in clinical trials for ulcerative colitis.",
                "relevance": 2
            },
            {
                "doc_id": "CPN71_4",
                "text": "A moderate body of evidence indicates adalimumab induces clinical remission and mucosal healing in patients with moderate-to-severe ulcerative colitis.",
                "relevance": 3
            },
            {
                "doc_id": "CPN71_5",
                "text": "Retrospective analyses suggest a moderate but clear advantage for adalimumab in achieving and maintaining steroid-free remission in UC.",
                "relevance": 3
            },
            {
                "doc_id": "CPN71_6",
                "text": "Gastroenterology guidelines recommend adalimumab as an effective biological therapy for moderate-to-severe ulcerative colitis.",
                "relevance": 4
            },
            {
                "doc_id": "CPN71_7",
                "text": "Randomized controlled trials and meta-analyses conclusively demonstrate adalimumab's superior efficacy over etanercept (which is ineffective) for inducing and maintaining remission in severe ulcerative colitis.",
                "relevance": 5
            }
        ]
    }
]